СОЕДИНЕНИЕ САХАРА

Изобретение относится к химической и биотехнологической промышленности. Соединение сахара получено путем воздействия на фукоидан эндофукоиданлиазы. Данное соединение обладает биологической активностью и его применение позволяет анализировать структуру фукоидана. 9 з.п. ф-лы, 42 ил., 2 табл.

СПОСОБЫ ВЫДЕЛЕНИЯ И ОЧИСТКИ ГАНГЛИОЗИДОВ

Группа изобретений относится к области биотехнологии. Способ выделения ганглиозида GM1 предусматривает получение тканей не бычьего и не свиного происхождения, содержащих клетки, продуцирующие GM1; выделение из указанных тканей клеток, продуцирующих ганглиозид GM1; экспансию указанных клеток, продуцирующих GM1, в культуре при подходящих условиях, способствующих экспансии указанных клеток; экспрессию ганглиозида GM1 в культуре при подходящих условиях; выделение указанного ганглиозида GM1 из указанной культуры, который может быть использован для лечения болезни Паркинсона и других неврологических заболеваний. Получение ганглиозида данным способом позволяет избежать возникновения прионных заболеваний при его дальнейшем использовании. 2 н. и 14 з.п. ф-лы, 7 ил., 2 табл., 4 пр.

СПОСОБ ПОЛУЧЕНИЯ МАКРОЦИКЛИЧЕСКОГО ЛАКТОНА

Изобретение относится к органической химии, в частности к способам получения соединения формулы (I): в которой m означает 0, 1 или 2; n означает 0, 1, 2 или 3 и А обозначает двойную связь, В обозначает двойную или простую связь, С обозначает двойную связь, D обозначает простую связь, Е и F обозначают двойную связь; r1 обозначает Н или С1-С8алкил; r2 обозначает Н, С1 -С8алкил или ОН; R3 и R4 каждый независимо друг от друга обозначают H или С1-С8алкил; R5 обозначает Н или С1 -С8 алкил; R6 обозначает Н; R7 обозначает ОН; R8 и R9 независимо друг от друга обозначают Н или С1-С10алкил; в свободной форме или в виде соли, заключающийся в том, что соединение формулы (II): вводят в контакт с биокатализатором, который способен избирательно окислять спирт в положении 4", с получением соединения формулы (III): в которых R1-R7, m, n, А, В, С, D, Е и F имеют те же значения, что и указанные выше для формулы (I), и соединение формулы (III) подвергают взаимодействию в присутствии восстановителя с известным ...

ПЕРЕРАБОТКА БИОМАССЫ

Изобретение относится к области биотехнологии, а именно к переработке биомассы. Предложен способ повышения доступности углеводов, содержащихся в исходном материале биомассы. Путем нарезания, растирания, раздавливания, дробления или рубки уменьшают размер исходного материала биомассы, содержащего полисахариды, выбранные из целлюлозы, пектина, гемицеллюлозы и их смесей. Получают исходную биомассу, содержащую менее 5% воды. Облучают исходную биомассу электронным пучком при уровне дозы от 1 до 10 Мрад/с и мощности от 1 до 500 кВт с получением первого обработанного материала биомассы. Охлаждают и снова облучают первый обработанный материал биомассы пучком электронов при уровне дозы от 1 до 10 Мрад/с и мощности от 1 до 500 кВт. Получают второй обработанный материал биомассы со среднечисленной молекулярной массой от 3000 до 50000 Дальтон и увеличенной доступностью углеводов. Изобретение позволяет получать материал, имеющий доступность питательных элементов, превышающую доступность питательных ...

МАЛЬТОБИОНАТ КАК АНТИОКСИДАНТ В ПИЩЕВЫХ ПРОДУКТАХ

... 1. Способ получения мальтобионата, включающий следующие стадии: ! a) получение субстрата, содержащего крахмал и/или мальтозу, применяемого в процессе получения пищевого и/или кормового продукта; ! b) превращение крахмала в мальтозу при использовании ферментативной реакции; и ! c) превращение мальтозы в мальтобионат при использовании ферментативной реакции. ! 2. Способ по п.1, в котором ферментативную реакцию стадии b) катализируют амилазой. ! 3. Способ по п.1, в котором ферментативную реакцию стадии c) п.1 катализируют оксидоредуктазой. ! 4. Способ по п.3, в котором оксидоредуктаза представляет собой карбогидратоксидазу. ! 5. Способ по п.4, в котором карбогидратоксидазу выбирают из группы, состоящей из гексозооксидаз, целлобиозооксидаз, альдозооксидаз и пиранозооксидаз. ! 6. Способ по п.4, в котором карбогидратоксидазу получают из Microdochium nivale, депонирован как CBS 100236. ! 7. Способ по любому из пп.1-6, в котором субстрат, содержащий крахмал и/или мальтозу стадии а) п.1, включает ...

СИНТЕЗ НОВЫХ ПРОИЗВОДНЫХ СИАЛООЛИГОСАХАРИДОВ

... 1. Способ синтеза соединений общей формулы 1A и их солейгде одна из групп R представляет собой α-сиалильную группировку, а другая представляет собой H, Xозначает углеводный линкер, A представляет собой D-глюкопиранозильное звено, необязательно замещенное фукозилом, Rпредставляет собой защитную группу, которая может быть удалена гидрогенолизом, целое число m равно 0 или 1, отличающийся тем, что сиалил-донор формулы SA-ORили его соль, где Rможет представлять собой моно-, ди- или олигосахарид, гликолипид, гликопротеин или гликопептид, циклическую или ациклическую алифатическую группу или арильный остаток, a SA представляет собой α-сиалильную группировку, вводят в реакцию с сиалил-акцептором общей формулы 2A или его солью,где X, A, m и Rявляются такими, как определено выше, в условиях катализа ферментом, обладающим транс-сиалидазной активностью.2. Способ по п.1, в котором фермент, обладающий транс-сиалидазной активностью, выбран из сиалидаз, получаемых из видов Bifidobacterium, и транс-сиалидаз ...

Новый сульфатированный фукоолигосахарид и способ его получения

Группа изобретений относится к биотехнологии. Предложены новый сульфатированный фукоолигосахарид формулы II, представленной на фиг.3, и способ его получения. Осуществляют обработку фукоидана из Sargassum horneri рекомбинантной фукоиданазой FFA1 в Tris-HCl буфере с рН 7,2 при 37°С в течение 72-75 ч. Затем нагревают до 100°C в течение 5-10 мин. Далее высокомолекулярные продукты гидролиза осаждают 75% водным раствором этанола или ацетона. Затем образовавшийся осадок отделяют с помощью центрифугирования при 9000-10000 g в течение 20-30 мин. Супернатант наносят на колонку с анионообменным сорбентом, уравновешенную водой, и элюируют фукоолигосахариды линейным градиентом гидрокарбоната аммония со скоростью 1 мл/мин. Сначала элюируют сульфатированный фукоолигосахарид формулы II, затем сульфатированный фукоолигосахарид формулы I. Полученные фракции целевых продуктов лиофильно высушивают. Изобретение расширяет арсенал сульфатированных фукоолигосахаридов, полученных из бурой водоросли Sargassum horneri ...

СПОСОБЫ ПОЛУЧЕНИЯ РАМНОЛИПИДОВ

СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ЧАСТИЦ, СОДЕРЖАЩЕЙ БЕЗВОДНУЮ КРИСТАЛЛИЧЕСКУЮ 2-О-α-D-ГЛЮКОЗИЛ-L-АСКОРБИНОВУЮ КИСЛОТУ

... 1. Способ получения композиции в форме частиц, содержащей безводную кристаллическую 2-O-α-D-глюкозил-L-аскорбиновую кислоту, включающий следующие стадии (a)-(e):(a) обеспечение воздействия цикломальтодекстринглюканотрансферазы на раствор, содержащий либо разжиженный крахмал, либо декстрин и L-аскорбиновую кислоту в качестве исходных материалов, и затем обеспечение воздействия глюкоамилазы на полученный раствор с получением раствора, содержащего 2-O-α-D-глюкозил-L-аскорбиновую кислоту, с выходом продуцирования 2-O-α-D-глюкозил-L-аскорбиновой кислоты по меньшей мере 27%;(b) очистка полученного раствора, содержащего 2-O-α-D-глюкозил-L-аскорбиновую кислоту, с получением содержания 2-O-α-D-глюкозил-L-аскорбиновой кислоты более 86%, в расчете на массу сухого твердого вещества;(c) осаждение безводной кристаллической 2-O-α-D-глюкозил-L-аскорбиновой кислоты из очищенного раствора с содержанием 2-O-α-D-глюкозил-L-аскорбиновой кислоты более 86%, в расчете на массу сухого твердого вещества, способом ...

СПОСОБЫ КОНТРОЛЯ ПЕНООБРАЗОВАНИЯ

... 1. Способ осуществления контроля над пенообразованием биосурфактанта, который вспенивается при своем вырабатывании клеткой-хозяином в ферментационной среде, когда клетка-хозяин выделяет в пространство вне клетки биосурфактант, причем биосурфактант растворим в ферментационной среде, включающий, одновременно с вырабатыванием биосурфактанта клеткой-хозяином, перевод биосурфактанта в нерастворимую форму, таким образом осуществляя контроль над пенообразованием, поскольку переведенный в нерастворимую форму биосурфактант не вспенивается.2. Способ по п. 1, где биосурфактант включает гидрофобин II, рамнолипид, софоролипид или сурфактин.3. Способ по п. 1, где коэффициент разрушения пены имеет значение больше чем 1, и/или коэффициент разрушения пены имеет значение больше чем 2, и/или коэффициент разрушения пены имеет значение больше чем 3; и/или концентрация растворимого биосурфактанта в ферментационной среде составляет не более примерно 1 г/кг; и/или не менее 25% получаемого биосурфактанта переводят ...

ПЕРЕРАБОТКА БИОМАССЫ

... 1. Способ изготовления корма для животных, включающийизменение молекулярной структуры полисахаридов биомассы, содержащей полисахариды в форме целлюлозы, гемицеллюлозы или крахмала, путем воздействия на биомассу излучением дозой по меньшей мере 5,0 Мрад, используя пучок электронов, работающий при мощности по меньшей мере 5 кВт, для получения пищевого материала, включающего материал, имеющий среднечисленную молекулярную массу от приблизительно 3000 до 50000 Дальтон, имеющего доступность питательных веществ по белку или аминокислоте, превышающую доступность питательных веществ по белку или аминокислоте биомассы,при этом доступность питательных веществ определяют путем скармливания равных количеств указанного пищевого материала и биомассы по меньшей мере двум различным группам, состоящим из одного или нескольких животных, и сравнения потерь с экскрементами белка или аминокислоты для этих двух групп;уплотнение пищевого материала с получением корма для животных; ипредоставление пищевого материала ...

Archaea und daraus erhaltene Lipidzusammensetzungen

Die vorliegende Erfindung betrifft Mikroorganismen, genauer Archaea, die bei Kultivierung bei 25°C ungesättigte Etherlipide in Mengen von mindestens 10% bezogen auf die Gesamtmenge an Etherlipiden aufweisen. In einem weiteren Aspekt richtet sich die vorliegende Erfindung auf Mikroorganismen innerhalb der Archaea, insbesondere aus solchen der Klasse Halomebacteria, insbesondere der Ordnung Halobacteriales, insbesondere der Familie Halobacteriaceae, insbesondere der Gattung Haloarcula bzw. Haloferax erhältlichen Lipidzusammensetzungen. Diese Lipidzusammensetzungen, insbesondere Liposomen, sind durch das Vorhandensein von großen Mengen an ungesättigten Etherlipiden gekennzeichnet. In einem weiteren Aspekt betrifft die vorliegende Erfindung ein Verfahren zur Gewinnung dieser ungesättigten Etherlipide aus den genannten Archaea.

PHARMAZEUTISCHE ZUBEREITUNG AUF DER BASIS VON RHAMNOLIPID GEGEN DERMATOLOGISCHE ERKRANKUNGEN

Verfahren zur enzymatischen Herstellung von Alpha-Glykosiden und deren Estern

PROCESS FOR ESTERIFICATION

NEUE MITTEL DC-92B UND DC-92D, SOWIE DEREN VERFAHREN ZUR HERSTELLUNG.

ENZYMATIC PRODUCTION OF PHOSPHOLIPID-SACCHARIDE DERIVATIVES

VERFAHREN ZUR ENZYMATISCHEN SYNTHESE VON SACCHARID-ESTERN

Verfahren zur Herstellung von Distearinsaeure-trehaloseester,Arthoronsaeureglukoseester und Mono- und Tristearinsaeure-saccharoseester

POLYPEPTIDE

PROCESS FOR PREPARING STARCH SUGARS CONTAINING ALDONIC ACIDS

... 1320165 Sugar acids HAYASHIBARA CO 5 June 1970 [6 June 1969] 27387/70 Heading C2C [Also in Division C3] Mixtures of aldonic acids, comprising gluconic, maltobionic and maltotrionic acids with oligosaccharides and dextrins are prepared by oxidizing the hydrolysate produced by the action of an acid or enzyme on a starch, with glucosedehydrogenase. The glucose-dehydrogenase producing micro-organisms of the species Pseudomonas may be cultured on a medium containing a starch hydrolysate as a carbon source to oxidize the starch hydrolysate which may be a second starch hydrolysate solution or may be the starch which is undergoing enzymatic saccharification with simultaneous hydrolysis and oxidation. Pseudomonas graveolens and fragi may be used as the glucose-dehydrogenase producing micro-organisms and the starch hydrolysates may have starch sugars containing more than 50% maltose with a D.E. of preferably at least 50. Examples describe the treatment of high maltose syrups obtained by the liquefaction ...

Microorganism production of high-valve chemical products, and related compositions, methods and systems

Enzymatic production of sucrose-6-ester, an intermediate for the manufacture of halo sugars

A novel process is described for production of 6-acyl-sucrose comprising enzymatic acylation of sucrose by an esterifying agent including an organic acid in presence of a lipase or an esterase in a solvent in which the enzyme used is stable. Chlorinated sucrose, the high intensity sweetener trichlorogalactosucrose can be prepared by chlorination and deacylation of 6-acyl sucrose prepared by the process of this invention.

Process for the isolation of polysaccharides and lipopolysaccarides having antigenicactivity

A polysaccharide or lipopolysaccharide which has antigenic activity is extracted from a microorganism, as defined below, which contains it, by treatment with a liquid dialkyl sulphoxide, with subsequent isolation of the polysaccharide or lipopolysaccharide from the dialkyl sulphoxide solution obtained. Microorganisms include all bacteria, yeasts, fungi, protozoa and higher parasites, but excludes viruses. Dimethyl sulphoxide is preferred, and the resulting isolation may be effected by fractional precipitation.ALSO:Polysaccharides and lipopolysaccharides having antigenic activity are extracted by means of dimethyl sulphoxide from micro-organisms (except viruses). In the Examples polysaccharides are extracted from the following microorganisms: Trichomonas vaginalis (Ex. 1), Candida albicans (Ex. 2), Mycobacteria tuberculosis (the solution also containing 0.1% of a polyethylenesorbitolmonooleate detergent) (Ex. 3), Saccharomyces cerevisiae (Bear yeast) (Ex. 4). Extraction is effected at 60 ...

Antimicrobial agent and method for the production thereof

ANTIBIOTIC A42867 DERIVATIVE

A-40104 antibiotics their preparation, use and formulations containing them

... {PG,1 A-40104 antibiotic complex, comprising active factors A, B, C, and D, produced by submerged aerobic fermentation of {i Clitopilus pseudo-pinsitus. {l Individual factors, A, B, and C have been isolated. A-40104 factor C is the known antibiotic pleuromutilin. A-40104 factors A and B are novel antibiotics related to pleuromutilin. A-40104 factor A, the major new factor, is the D-xylose acetal derivative of pleuromutilin. A-40104 factors A and B, their 19,20-dihydro derivatives and the per(C{HD 2{L {14 C{HD 6{L )alkanoyl derivatives of factors A and B and of their 19,20-dihydro derivatives are active against gram-positive and gram-negative bacteria, anaerobic bacteria, and Mycoplasma.

Processing biomass.

Antifungal sordan derivatives.

A compound of formula ...

Hygromycin A derivatives.

This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein r1 and r2 are as defined herein. The compounds of formula 1 ae antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

PROCESSING BIOMASS

Hygromycin A derivatives.

This invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1 is H and R2-NR3R4,-NR4C(0)R3,-0C(0)NR3R4 or-0R3 or other substituents as set out in the disclosure hereto. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

Hygromycin a derivative

Radiant energy collecting apparatus

PROCESSING BIOMASS

Hygromycin derivatives

Processing biomass.

Hygromycin A derivatives.

Antifungal sordaridin derivatives

PROCESSING BIOMASS

PROCESSING BIOMASS

Radiant energy collecting apparatus

Hygromycin derivatives

Processing biomass.

USTILIPIDE, PROCEDURE FOR THEIR PRODUCTION AS WELL AS THEIR USE

EZYMATI PROCEDURE FOR the PRODUCTION OF 2-OGLYCERYL-ALPHA-D-GLUCOPYRANOSID

PHENOLIC CONNECTIONS WITH COSMETIC AND THERAPEUTIC APPLICATIONS

BACTERIAL ANTIGENS AND THEIR USE

SUGAR CONNECTIONS

PROCEDURE FOR THE ENZYMATIC PRODUCTION OF ALPHA GLYKOSIDEN AND THEIR ESTERS

PROCEDURE FOR FERMENTATIVEN THE OXIDATION OF REDUCTIONS DISACCHARIDE.

2-HYDROXY-1,2,4-BUTANTRICARBONSAEURE-OLIGORIBOSI - DERIVATIVES, PROCEDURES FOR YOUR PRODUCTION AND YOUR USE AS PREVENTIVE MEANS AGAINST ZAHNKARIES.

ANTIBIOTICS AND PROCEDURES FOR THEIR PRODUCTION.

ANTI-FR-900506-STOFFE-ANTIKOERPER AND HOECHSTEMPFINDLICHES ENZYME IMMUNOASSAY PROCEDURE.

NEW SPHINGOGLYCOLIPIDE AND USE OF IT

ANTIBIOTIC LL-E19020 ALPHA

PROCEDURE FOR THE PRODUCTION OF ALKYGLYCOSIDE ESTERS.

NEW CONNECTIONS KF-1040 AND PROCEDURE FOR YOUR PRODUCTION

PROCEDURE FOR THE PRODUCTION OF A COMPOSITION, WHICH CONTAINS HYGROMYCIN A AND EPI HYGROMYCIN

TRICYCLI CONNECTIONS, PROCEDURES FOR YOUR PRODUCTION AND THIS CONTAINING PHARMACEUTICAL COMPOSITION.

BY AROMATICS SUBSTITUTED GLYKOSID

VANCORESMYCIN, PROCEDURES FOR ITS PRODUCTION AND ITS APPLICATION AS DRUGS

PHARMACEUTICAL PREPARATION ON THE BASIS OF RHAMNOLIPID AGAINST DERMATOLOGI ILLNESSES

ENZYMATIC PRODUCTION OF PHOSPHOLIPIDEN IN AQUEOUS MEDIA

PROCEDURE FOR ENZYMATIC SPLITTING OF RUTINOSIDEN

PSEUDOMONAS AERUGINOSA AND ITS USE FOR THE PRODUCTION OF L-RHAMNOSE ONES

KIJANIMICIN

ABC transporters for the high efficiency production of rebaudiosides

Provided herein are genetically modified host cells, compositions, and methods for improved production of steviol glycosides. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleic acid expression cassette that expresses an ABC-transporter capable of transporting steviol glycosides to the extracellular space or to the luminal space of an intracellular organelle. In some embodiments, the host cell further comprises one or more heterologous nucleotide sequence encoding further enzymes of a pathway capable of producing one or more steviol glycosides in the host cell. The host cells, compositions, and methods described herein provide an efficient route for the heterologous production of steviol glycosides, including but not limited to, rebaudioside D and rebaudioside M.

PSEUDOOLIGOSACCHARIDES WITH AN ALPHA-GLUCOSIDASE - INHIBITING ACTION

Enzymatic preparation of phospholipids in aqueous media

Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives

Bacterial antigens and uses thereof

Glucuronyltransferase and polynucleotide encoding the same

Protein

A fungal wild-type lipolytic enzyme having a higher ratio of activity on polar lipids compared with triglycerides, wherein the enzyme preferably has a phospholipidAriglyceride hydrolysing activity ratio of at least 4. Preferably, the lipolytic enzyme according to the present invention has a glycolipid:triglyceride hydrolysing activity ratio of at least 1.5. In one embodiment, the fungal lipolytic enzyme according to the present invention comprises an amino acid sequence as shown in SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 6 or an amino acid sequence which has at least 90% identity thereto. The present invention further encompasses a nucleic acid encoding a fungal lipolytic enzyme, which nucleic acid is selected from the group consisting of: (a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3, SEQ ID No. 5 or SEQ ID No. 7; (b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3, SEQ ID No. 5 or SEQ ID No. 7 by the degeneration ...

A method of glycosylating a lipid

Materials and methods for the control of nematodes

The invention provides materials and method for controlling pests, in particular, nematodes. The invention also provides compositions comprising biosurfactants as pesticides.

Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma

Antifungal sordaridin derivatives

PROCESS FOR THE PREPARATION OF A MACROCYCLIC COMPOUND

Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections

Hygromycin a derivatives

ANTIMICROBIAL MOLECULE

The present invention relates to a compound having antimicrobial activities. The present invention also provides methods for the production and purification of flocculosin, the antimicrobial compound of the invention, including the steps of cultivating the microorganism Pseudozyma flocculosa. Analogs and derivatives of flocculosin are described herein.

PROCESS FOR PRODUCING PURIFIED ANTHOCYANIN AND CRYSTALLINE ANTHOCYANIN

A process for producing purified anthocyanidin glucoside characterized by comprising cleaving the rhamnose end of anthocyanidin rutinoside with rhamnosidase, converting the anthocyanidin rutinoside component into anthocyanidin glucoside and then purifying and isolating the anthocyanidin glucoside component; or a crystalline anthocyanidin glucoside salt obtained by further crystallizing the purified anthocyanidin glucoside and a process for producing the same. A process for producing anthocyanidin rutinoside characterized by comprising cleaving the glucose end of anthocyanidin glucoside with .beta.-glucosidase, eliminating via decomposition and then purifying and isolating the anthocyanidin rutinoside component; or a crystalline anthocyanidin rutinoside salt obtained by further crystallizing the purified anthocyanidin rutinoside and a process for producing the same.

MICROBIOLOGICAL PROCESS FOR THE PREPARATION OF ANTHRACYCLINE DERIVATIVES

... of the disclosure: The present application relates to a microbiological process for the preparation of compounds of the formula I I in which R denotes hydrogen or hydroxyl and R1 and R2 are identical or different and represent sugar combinations of the following composition: - Roa-dF-CinA - Roa-dF-Acu - Roa-dF=CinB - Roa-Rod-CinA or - Roa-Rod-Acu or R2 has the abovementioned meanings and R1 represents sugar combinations of the following composition: - Roa-dF-Rod - Roa-dF-CinB - Roa-dF-Acu - Roa-Rod-Acu - Roa-dF-CinA - Roa-Rod-Rod or - Roa-Rod-CinA in which Roa denotes rhodosamine; dF denotes deoxyfucose; Rod denotes rhodinose; Acu denotes aculose; CinA denotes cinerulose A and CinB denotes cinerulose B, and dF = CinB means that the two sugar units deoxyfucose and cinerulose B are linked by an extra ether bridge, in addition to the usual glycosidic bond, which comprises reacting a compound of the formula II II in which R denotes hydrogen or hydroxyl and R3 and R4 are identical ...

COMPOSITIONS FOR REPLACING CHEMICAL SURFACTANTS

The subject invention provides methods and compositions for replacing chemical surfactants for use in a wide variety of industrial applications. More specifically, the subject invention provides for the production of multi-functional biological surface-active compositions having one or more precise functional characteristics based on the desired use.

PROCESS FOR THE BIOTECHNICAL PRODUCTION OF RHAMNOLIPIDS AND RHAMNOLIPIDS WITH ONLY ONE .beta.- HYDROXYDECANE CARBOXYLIC ACID RESIDUE IN THE MOLECULE

PROCESS FOR THE PRODUCTION OF PHOSPHOLIPIDS

A process for the production of phospholipids by transphosphatidylation, which comprises the step of mixing a starting phospholipid with a receptor having one or more hydroxyl groups, phospholipase D and water in the absence of an organic solvent and homogenizing the resulting mixture and the step of subjecting the obtained homogeneous mixture to a reaction at 15 to 65~C. The homogeneous mixture has a lamellar lyotropic liquid crystal structure and can give an objective phospholipid via transphosphatidylation without using an organic solvent or calcium.

WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES

The invention relates to the preparation of phenolics derivatives by enzy matic condensation of phenolics selected among pyrocatechol or its derivativ es with the glucose moiety of sucrose. The production of said phenolics deri vatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-.alpha. -glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmet ic and pharmaceutical compositions, such as antioxidative, antiviral, antiba cterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, a ntiarrhytmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepat oprotective, anti-inflammatory, anticarcinogenic antimutagenic, antineoplast ic, anti-thrombotic, and vasodilatory formulations, or in any other field of application.

QUANTITATIVE CONTROL OF SIALYLATION

The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. Contrary to previous findings certain truncations were found to exhibit sialidase enzymatic activity, particularly a variant of human sialyltransferase (hST6Gal-I) with a truncation deletion involving the first 89 N-terminal amino acids of the respective wild-type polypeptide. A fundamental finding documented in the present disclosure is that there exists a variant of this enzyme which is capable of catalyzing transfer of a glycosyl moiety as well as hydrolysis thereof. Thus, disclosed is a specific exemplary variant of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variant of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.

METHOD FOR PREPARING MOGROSIDE

The present invention provides a method for preparing a mogroside that does not have a ß1,6-glucoside bond, said method comprising a step for reacting glycosidase ASBGL2, AOBGL2, AOBGL1, ASBGL1, or a variant thereof with a mogroside having at least one ß1,6-glucoside bond so as to cut the ß1,6-glucoside bond.

CELLS AND METHODS FOR PRODUCING RHAMNOLIPIDS

The invention relates to cells and nucleic acids and also use thereof for producing rhamnolipids, and also methods for producing rhamnolipids.

METHODS OF FOAM CONTROL

The invention relates to a method for decreasing foam formation as well as maximizing expression of a biosurfactant in a microorganism. The methods encompasses precipitating biosurfactant from the microorganism which results in decreased form formation.

BIODEGRADABLE SUGAR-BASED POLYMER

... 2063445 9117255 PCTABS00008 A method of making a sugar-based polymer is disclosed. A sugar and an organic acid derivative having at least two carboxylate functionalities are mixed in a substantially non-aqueous organic solvent with a hydrolytic enzyme and, thereafter, the resulting mixture is agitated for a time sufficient to allow for the polymerization of the sugar. The resulting sugar-based polymer has sugar incorporated in the polymer backbone.

ANTITUMOR ANTIBIOTIC BMY-41339

A novel antitumor antibiotic designated BMY-41339 is produced by fermentation of certain strains of Actinomadura verrucosospora. BMY-41339 exhibits antimicrobial activity and also inhibits the growth of tumors in expetimental animals.

GALACTOPYRANOSIDES AND THEIR USE

The present invention relates to simplified synthesis, new carbohydrate-based products and practical use of different carbohydrate-based products. Examples of these are (Gal.alpha.1-3Gal), GlcNAc.beta.1-3Gal, .alpha.- or .beta.glycosides thereof, Gal.alpha.1-3Gal- containing tri-, or higher oligosaccharides, .alpha.- or .beta.-glycosides thereof, GlcNAc.beta.1-3Gal containing tri-, tetra-, or higher oligosaccharides, and derivatives and/or .alpha.- or .beta.-glycosides thereof, Gal.alpha.1-3GalGlcNAc.beta.1-3Gal, .alpha.- or .beta.-glycosides thereof, Gal.alpha.1-3Gal.beta.1-4GlcNAc.beta.1-3Gal.beta.1-4Glc, or other higher oligosaccharides containing the Gal.alpha.13Gal-structure, .alpha.- or .beta.-glycosides thereof, modified carbohydrates, di-, tri-, oligo-, or polyfunctional products containing carbohydrate structures, and the use of the products for synthesis, affinity purification, diagnostic applications and therapy.

NOVEL SUBSTANCES KF-1040 AND PROCESS FOR PRODUCING THE SAME

A process for producing a substance KF-1040A represented by formula (I), and another substance KF-1040B represented by formula (II), which comprises culturing microorganisms capable of producing the substances KF-1040A and KF1040B, thus accumulating these KF-1040A and/or KF-1040B in the liquid culture and harvesting the same from the culture. Because of the activities of inhibiting diacyloglycerol transferase and sphingomyelinase, the above substances are useful in preventing and treating arteriosclerosis, obesity, thrombus, inflammation and immune function-related diseases.

NOVEL SUBSTANCES KF-1040 AND PROCESS FOR PRODUCING THE SAME

A process for producing a substance KF-1040A represented by formula (I), and another substance KF-1040B represented by formula (II), which comprises culturing microorganisms capable of producing the substances KF-1040A and KF-1040B, thus accumulating these KF-1040A and/or KF-1040B in the liquid culture and harvesting the same from the culture. Because of the activities of inhibiting diacyloglycerol transferase and sphingomyelinase, the above substances are useful in preventing and treating arteriosclerosis, obesity, thrombus, inflammation and immune function-related diseases.

Verfahren zur Herstellung eines neuen Antibiotikums

Procédé de préparation de lipides purifiés à partir de lipides bruts dérivés des lipopolysaccharides de bactéries à gram-négatif

Purified Ethyl Ester Sophorolipid for the Treatment of Sepsis

A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola . The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then decanted as a dense oil from the culture broth, subsequently washed to remove free fatty acids. Secondary chemical transformation via base catalyzed hydrolysis is used to reduce the 8 possible structural sophorolipid species to a single moiety, the 17-L-[(2′-O-b-D-glucopyranosyl-b-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de-acetylated free acid. The compound acts primarily through decreasing inflammatory cytokines and eliciting other synergistic anti-inflammatory mechanisms by blocking TLR4-CD14 upstream of the inflammatory signaling cascade. The compound can be administered either intraperitoneally or intravenously at single or multiple doses of 5-30 mg/kg of weight in solvent media or in capped nanoparticles, preferably within 48 hours of sepsis inception.

Virucidal properties of various forms of sophorolipids

A method for neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having antiviral properties produced by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as an antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an antiviral agent, and sophorolipid compounds for use as antiviral agents.

Sophorolipid transporter protein

The invention relates to a transporter protein involved in the transport of sophorolipids. More specifically, it relates to a Candida bombicola sophorolipid transporter protein, and the use of this transporter to modulate the secretion and/or production of glycolipids, preferably sophorolipids in organisms, preferably in fungi.

Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Cells and methods for producing rhamnolipids

The invention relates to cells and nucleic acids and also use thereof for producing rhamnolipids, and also methods for producing rhamnolipids.

Methods of Ganglioside Production

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

NOVEL FUCOSYLTRANSFERASES AND THEIR APPLICATIONS

The present invention relates to nucleic acid and amino acid sequences from and from , coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose. 1. Isolated polynucleotide encoding a polypeptide with alpha-1 ,3-fucosyltransferase activity and comprising a nucleic acid sequence selected from the group consisting of:a) SEQ ID Nos. 1, 3, or 5 of the attached sequence listing;b) a nucleic acid sequence complementary to SEQ ID Nos. 1, 3, or 5;c) nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequences defined in a) and b) or their complementary strands.2. The isolated polynucleotide of consisting of the SEQ ID Nos. 1 claim 1 , 3 claim 1 , or 5 encoding a polypeptide with alpha-1 claim 1 ,3 fucosyltransferase activity.3. Vector claim 1 , containing a nucleic acid sequence as claimed in encoding a polypeptide with alpha-1 claim 1 ,3-fucosyltransferase activity claim 1 , the nucleic acid sequence being operably linked to control sequences recognized by a host cell transformed with the vector.4. An isolated polypeptide with alpha-1 claim 1 ,3-fucosyltransferase activity consisting of an amino acid sequence selected from the group consisting of:(a) an amino acid sequence shown in SEQ ID NO. 2, 4, or 6;b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID No. 2, 4, or 6, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID Nos. 1, 3, or 5;c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID No. 2, 4, or 6, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a ...

Methods of Ganglioside Production

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. The method of claim 5 , wherein said fibroblast cell is a fibroblast from a human with GM1 gangliosidosis.8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

Process for producing a particulate composition comprising anhydrous crystalline 2-o-alpha-d-glucosyl-l-ascorbic acid

The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside.

THERMO-PHOTO-BIOREACTOR AND METHOD FOR THE CULTURE AND MASS MICROPROPAGATION OF DESCHAMPSIA ANTARCTICA IN VITRO

The invention relates to a thermo-photo-bioreactor and to a method for the culture and mass micropropagation of in vitro. The invention comprises a discontinuous immersion reactor for biomass micropropagation, including means for incorporating chemical inducing agents (salt, metals, organic compounds, etc.) and internal luminescence or illumination means (UV radiation and temperature) for supplying said chemical inducers and/or illumination during any growth phase of the vegetable or plant material (multiplication or propagation and/or maintenance). The invention is advantageous in that it can be used to produce large quantities of biomass of the aforementioned Antarctic species, while providing conditions suitable for said plant to produce metabolites that can be used for human health and personal care. 1Deschampsia antarcticaD. antarctica. A method for an in vitro culture and mass micropropagation of () , plant material , further inducing generation or biosynthesis of antioxidant and photoprotective metabolites characteristic of said plant material , such as scopoletin , chlorogenic acid , rutin , and quercetin , comprising the following steps:{'i': 'Deschampsia antarctica;', 'a) collecting parent plant material consisting of'}b) recovering said plant material from the collected parent material;c) inoculating said plant material shoots;{'i': 'D. antarctica', 'd) in vitro culturing and micropropagating said plant material by temporary immersion in MS Basal Medium (PhytoTech Lab™) that further comprises sugars, hormones, vitamins and cytokines and is at a pH between 5-6, under temperature conditions that simulate those of natural habitat;'}e) inducting the plant material of secondary compounds production by applying UV-B lighting pulses,wherein the following are used in step d): sugars selected from saccharose glucose or fructose; hormones selected from benzyl amino purine (BAP), isopentenyl adenine (2IP), indole butyric acid (IBA), GA3 or a mixture thereof; ...

Method for utilizing monoterpene glycosyltransferase

The object of the present invention is to provide a novel method for producing a terpene 8-glycoside. The present invention provides a method for producing a terpene 8-glycoside by means of glycosyltransferase acting on the 8-position of terpenes. The present invention provides a transformant transformed with a gene for the glycosyltransferase acting on the 8-position of terpenes and a method for producing such a transformant. The present invention provides a plant modified to suppress the expression of a protein having glycosylation activity on the 8-position of a monoterpene compound.

Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives

The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application.

HIGH-PURITY RUBUSOSIDE AND PROCESS FOR PRODUCING OF THE SAME

The invention provides a process of producing Rubusoside from steviol glycosides of plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. 1Stevia rebaudiana. A process for preparing Rubusoside from steviol glycosides of comprising the steps of:{'i': 'Stevia rebaudiana;', 'a. providing initial steviol glycosides of'}b. dissolving the initial steviol glycosides in the water;c. providing an enzyme with glycosyl hydrolase activity to obtain reaction mixture;d. incubating the reaction mixture to facilitate complete or partial transformation of Stevioside to Rubusoside;e. terminating the reaction by thermal inactivation of enzyme;f. recovering and purifying high purity Rubusoside from reaction mixture.2Stevia. A process of wherein step (a) the steviol glycoside is extract claim 1 , mixture of steviol glycosides or pure Stevioside.3. A process of wherein step (b) the concentration of dissolved steviol glycosides is 1-50% (wt/vol) claim 1 , preferably 5-30% (wt/vol) claim 1 , more preferably 8-10% (wt/vol).4. A process of wherein step (c) the enzyme is selected from the group of rhamnosidase claim 1 , β-glucosidase claim 1 , hesperidinase claim 1 , naringinase claim 1 , pectinase claim 1 , cellulase claim 1 , and other enzymes with glycosyl hydrolase activity claim 1 , in free or immobilized forms.5. A process of wherein step (d) the molar yield of Rubusoside from Stevioside is 1-100% claim 1 , preferably 80-100% and more preferably 95-100%.6. A process of wherein step (e) the reaction termination includes heat treatment claim 1 , activated carbon treatment.7. A process of ...

IMMUNOTHERAPEUTIC POTENTIAL OF MODIFIED LIPOOLIGOSACCHARIDES/LIPID A

Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases. 1. A method of generating a lipooligosaccharide/lipid A-based mimetic , comprising the steps of: expresses one or more non-endogenous lipid A biosynthesis enzymes;', 'expresses one or more endogenous lipid biosynthesis enzymes, wherein the enzyme is modified; and/or', 'has modified regulation of one or more endogenous lipid biosynthesis enzymes; and, 'obtaining a bacterial strain that has one or more of the following modificationssubjecting the strain to conditions suitable for production of the lipooligosaccharide/lipid A composition.2. The method of claim 1 , wherein the obtaining step is further defined as engineering the bacterial strain to have one or more of the modifications.3. The method of claim 2 , wherein the engineering step comprises one or both of:delivering a vector into the bacteria; orbacterial conjugation.4. The method of claim 2 , wherein the engineering step comprises delivering a vector into the bacteria claim 2 , wherein the vector comprises sequence that encodes one or more non-endogenous lipid A biosynthesis enzymes.5. The method of claim 1 , wherein the lipooligosaccharide/lipid A-based mimetic produced by the method has a modified number of phosphates compared to the endogenous bacterial lipid A molecule or a reference lipid A molecule.6. The method of claim 1 , wherein the lipooligosaccharide/lipid A-based mimetic produced by the method has modified phosphates compared to the endogenous bacterial lipid A molecule or a reference lipid A molecule.7Yersinia pestis, Pseudomonas. The method of claim 1 , wherein the bacterial strain is claim 1 , ...

METHOD FOR PREPARING MOGROSIDE

The present invention provides a method for preparing a mogroside having no β-1,6-glucoside bond comprising the step of reacting glycosidase ASBGL2, AOBGL2, AOBGL1, ASBGL1, or a variant thereof with a mogroside having at least one β-1,6-glucoside bond, thereby cleaving said β-1,6-glucoside bond. 1. A method for preparing a mogroside having no β-1 ,6-glucoside bond comprising reacting a protein selected from the group consisting of proteins (a) to (c) shown below with a mogroside having at least one β-1 ,6-glucoside bond , thereby cleaving said β-1 ,6-glucoside bond:(a) a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, and SEQ ID NO: 16;(b) a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, and SEQ ID NO: 16, wherein 1 to 84 amino acids have been deleted, substituted, inserted, and/or added, and having an activity to cleave a β-1,6-glucoside bond of a mogroside; and(c) a protein having an amino acid sequence having 90% or more sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, and SEQ ID NO: 16, and having an activity to cleave a β-1,6-glucoside bond of a mogroside.2. The method according to claim 1 , wherein the protein selected from the group consisting of proteins (a) to (c) further includes a secretory signal peptide.3. The method according to claim 1 , wherein the mogroside having at least one β-1 claim 1 ,6-glucoside bond further has at least one β-1 claim 1 ,2-glucoside bond.4. The method according to claim 3 , wherein the mogroside having at least one β-1 claim 3 ,6-glucoside bond and at least one β-1 claim 3 ,2-glucoside bond is selected from mogroside V claim 3 , siamenoside I claim 3 , mogroside IV claim 3 , and mogroside IIIA.5. The method according to claim 4 , wherein the mogroside having no β-1 claim 4 ,6-glucoside bond is ...

IMPROVED PRODUCTION OF SYMMETRICAL BOLAFORM SOPHOROSIDES

The present invention relates to the field of microbial production of novel biosurfactants. More specifically, the present invention discloses the usage of a fungal strain such as the yeast Starmerellabombicola having a dysfunctional CYP52M1 cytochrome P450 monooxygenase and a dysfunctional FAO1 fatty alcohol oxidase for producing high amounts of so-called “symmetrical bolaform sophorosides” where both sophorose moieties are attached through a terminal glycosidic linkage to the hydrophobic linker. In addition, the present invention further discloses that the latter yeast can also be used to produce alkyl sophorosides and symmetrical bolaform glucosides. 1StarmerellaCandidabombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellate, Candida kuoi, Candida, RhodotorulabogoriensisWickerhamiella domericqiaeStarmerella. A method to produce fully symmetrical bola sophorosides which are free from contaminating fatty acid containing sophorolipids comprising feeding a mutated fungal strain with a fatty alcohol having an aliphatic tail chain length of at least 6 carbons wherein said fungal strain has a dysfunctional CYP52M1 cytochrome P450 monooxygenase and a dysfunctional FAO1 fatty alcohol oxidase and wherein said fungal strain is a yeast selected from the group consisting of () sp. NRRL Y-27208sp. , and a sophorolipid-producing strain of the clade.2. A method according to wherein the gene encoding for the CYP52M1 cytochrome P450 monooxygenase and the gene encoding for the FAO1 fatty alcohol oxidase are knocked out.3. A method according to claim 1 , wherein said fatty alcohol having an aliphatic tail chain length of at least 6 carbons is hexanol claim 1 , octanol claim 1 , decanol claim 1 , undecyl alcohol claim 1 , lauryl alcohol claim 1 , tridecyl alcohol claim 1 , myristyl alcohol claim 1 , pentadecyl alcohol claim 1 , cetyl alcohol claim 1 , palmitoleyl alcohol claim 1 , heptadecyl alcohol claim 1 , stearyl alcohol claim 1 , ...

Methods For Selecting Microbes From A Diverse Genetically Modified Library to Detect and Optimize the Production of Metabolites

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

METHOD FOR PREPARING SALIDROSIDE

The present invention provides a method for preparing salidroside. The present invention uses β-glucoside and CoFeOparticles to form a cross-linked aggregate capable of effectively catalyzing the reaction of β-D-ghucose and tyrosol, thereby increasing the yield of the salidroside. The steps of the preparation method of the present invention are simple and short, and the method is easy to operate and readily applicable to industrial production. 1. A method for preparing salidroside , comprising the following steps:{'sub': 2', '4, '(1) adding β-glucosidase into a phosphate-citric acid buffer solution, adding polyacrylamide cross-linked hollow CoFeOparticles, adding a settling agent, glutaraldehyde and sodium borohydride after oscillating, oscillating, centrifuging same at 320-480 rpm for 5-10 min, feeding same into a thermostatic water bath at 40-45° C., keeping the temperature and stirring same for 1-2 h, discharging, and collecting precipitates to obtain a β-glucosidase cross-linked aggregate;'}(2) adding β-D-glucose and tyrosol into a solvent, adding the buffer solution and the β-glucosidase cross-linked aggregate obtained in the step (1), and reacting to obtain a reaction solution; and(3) filtering the reaction solution obtained in the step (2), and carrying out reduced pressure distillation on a filtrate to obtain a crude product; and recrystallizing the crude product to obtain the salidroside.2. The method for preparing the salidroside according to claim 1 , wherein a method for preparing the polyacrylamide cross-linked hollow CoFeOparticles comprises the following steps:(1) adding 1-2 parts by weight of ammonium persulfate into deionized water which is 20-30 times of the weight of the ammonium persulfate, and uniformly stirring same; and{'sub': 2', '4, '(2) adding 40-45 parts by weight of methyl methacrylate into the deionized water which is 5-8 times of the weight of the methyl methacrylate, uniformly stirring same, feeding same into a reaction kettle, ...

Synthesis of new sialooligosaccharide derivatives

The invention relates to a method for the synthesis of compounds of general formula (1A) and salts thereof wherein one of the R groups is an α-sialyl moiety and the other is H, X 1 represents a carbohydrate linker, A is a D -glucopyranosyl unit optionally substituted with fucosyl, R 1 is a protecting group that is removable by hydrogenolysis, the integer in is 0 or 1, by a transsialidation reaction.

GANGLIOSIDE COMPOSITIONS

The invention provides novel gangliosides and mixtures of novel gangliosides, and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A ganglioside characterized by a single thin layer chromatography (“TLC”) band having a retardation factor (“Rf”) value that is greater than an ovine GM1 standard Rf when said ganglioside is subjected to TLC on a glass plate coated with a 250 μm layer of ultrapure silica gel and contacted with a solution comprising chloroform , methanol and 0.2% calcium in a ratio of 50:42:11 , after which said coated glass plate is stained by being placed into a second solution comprising 80 mL of concentrated hydrochloric acid , 0.25 mL of 0.1 M cupric sulfate , 10 mL of 2% resorcinol and 10 mL of water , and said glass plate is heated in said second solution for 20 minutes at 100° C. , wherein said ganglioside comprises one or more gangliosides.2. The ganglioside of claim 1 , wherein said ganglioside is purified from a crude ganglioside mixture.3. The ganglioside of claim 2 , wherein said crude ganglioside mixture is isolated from adult human bone marrow stromal cells cultured under low oxygen.4. The ganglioside of claim 3 , wherein said low oxygen is 5% oxygen.5. The ganglioside of claim 1 , wherein said ganglioside Rf value is 0.65.6. The ganglioside of claim 1 , ...

BIOSYNTHESIS PRODUCTION OF STEVIOL GLYCOSIDES AND PROCESSES THEREFORE

The present invention relates to the production of steviol glycoside rebaudiosides D4, WB1 and WB2 and the production of rebaudioside M from Reb D4. 154.-. (canceled)56Pichia pastoris. The reaction mixture of claim 55 , wherein the beta-glucosidase is a beta-glucosidase.57. The reaction mixture of claim 55 , wherein the beta-glucosidase comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 5.58. The reaction mixture of claim 55 , wherein the beta-glucosidase comprises the amino acid sequence of SEQ ID NO: 5.59. The reaction mixture of claim 55 , wherein the polynucleotide comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO: 6.60. The reaction mixture of claim 55 , wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 6.61. The reaction mixture of claim 55 , wherein the cell is a yeast cell.62. The reaction mixture of claim 55 , wherein the cell is a bacterial cell.63. The reaction mixture of claim 55 , wherein the cell is a plant cell.65. The reaction mixture of claim 64 , wherein the UDP glycosyltransferase comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 9.66. The reaction mixture of claim 64 , wherein the UDP glycosyltransferase comprises the amino acid sequence of SEQ ID NO: 9.67. The reaction mixture of claim 64 , wherein the polynucleotide comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO: 10.68. The reaction mixture of wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 10.69. The reaction mixture of claim 64 , wherein the cell is a yeast cell.70. The reaction mixture of claim 64 , wherein the cell is a bacterial cell.71. The reaction mixture of claim 64 , wherein the cell is a plant cell.72. The reaction mixture of claim 64 , further comprising a substrate selected from the group consisting of: sucrose claim ...

PROCESSING BIOMASS

Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids. 1. A method of producing a polyester polymer comprising:(i) saccharifying biomass to form a saccharified biomass;(ii) contacting the saccharified biomass with a microorganism to produce one or more products; and(iii) converting the one or more products to the polyester polymer.2. The method of claim 1 , wherein the polyester polymer comprises poly(lactic acid).3. The method of claim 1 , wherein the one or more products comprises an organic acid.4. The method of claim 3 , wherein the organic acid comprises lactic acid.5. The method of claim 1 , wherein the microorganism comprises a lactic acid bacteria (LAB).6Lactobacillus.. The method of claim 1 , wherein the microorganism comprises a species in the genera7. The method of claim 1 , further comprising treating the biomass prior to step (i) to reduce its recalcitrance.8. The method of claim 7 , wherein the treating comprises size reduction (e.g. claim 7 , mechanical size reduction of individual pieces of biomass) claim 7 , radiation claim 7 , sonication claim 7 , pyrolysis claim 7 , or oxidation9. The method of claim 7 , wherein the treating comprises radiation claim 7 , e.g. claim 7 , using ionizing radiation.10. The method of claim 7 , wherein the recalcitrance of the biomass is reduced by at least about 10%.11. The method of claim 7 , wherein the recalcitrance of the biomass is reduced by 50%-90%.12. The method of claim 1 , wherein the biomass is a lignocellulosic or cellulosic material.13. The method of claim 1 , wherein the biomass comprises paper claim 1 , paper products claim 1 , paper waste claim 1 , wood claim 1 , particle board claim 1 , sawdust claim 1 , agricultural waste claim 1 , sewage claim 1 , silage claim 1 , grasses claim 1 , rice hulls claim 1 , bagasse claim 1 , cotton claim 1 , jute claim 1 , hemp claim 1 , flax claim 1 , bamboo ...

Production of Steviol Glycosides in Recombiant Hosts

The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors. 1. A recombinant host cell producing a steviol glycoside in a cell culture , wherein the recombinant host cell has a modified expression of an endogenous transporter gene encoding a transporter polypeptide , wherein the modified expression comprises increasing expression or activity of the endogenous transporter gene encoding the transporter polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:38 above the level of expression or activity observed in a corresponding unmodified recombinant host cell;wherein at least a portion of the steviol glycoside is transported from the recombinant host into the cell culture medium; andwherein the host cell is a plant cell, a fungal cell, or a bacterial cell.2. The recombinant host cell of claim 1 , wherein the transporter polypeptide comprises a mitochondrial protein translocase (MPT) transporter polypeptide.3. The recombinant host cell of claim 1 , further comprising:(a) one or more genes encoding a sucrose transporter (SUC1) polypeptide and a sucrose synthase (SUS1) polypeptide; 'wherein the polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:149;', '(b) a gene encoding a polypeptide capable of synthesizing geranylgeranyl pyrophosphate (GGPP) from farnesyl diphosphate (FPP) and isopentenyl diphosphate (IPP);'} 'wherein the polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:150;', '(c) a gene encoding a polypeptide capable of synthesizing ent-copalyl diphosphate from GGPP;'} 'wherein the polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:152;', '(d) a gene encoding a polypeptide capable of synthesizing ent-kaurene from ent-copalyl ...

Algae cultivation method and production method for osmotic pressure regulator

An algae culture method capable of efficiently producing an osmotic pressure adjusting substance, a production method of the substance, and an algae culture method for recovering carbon dioxide from a mixed gas containing carbon dioxide and sulfurous acid gas. The methods involve preparing a plurality of enrichment cultures each containing betaine by culturing a culture of microalgae derived from an environmental specimen under a photoautotrophic condition and under a plurality of culture conditions; making a cultivation plan in which an optimum enrichment culture suitable for a main culture is selected from the plurality of enrichment cultures; producing a main culture that contains betaine under the photoautotrophic condition and a salt concentration of 10 wt. % or more; and separating betaine. In the main culture, the algae containing betaine are cultured while the mixed gas containing sulfurous acid gas and carbon dioxide is blown to a culture solution of the algae.

MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES

The invention provides materials and method for controlling pests, in particular, nematodes. The invention also provides compositions comprising biosurfactants as pesticides. 1. A method for controlling nematodes wherein said method comprises contacting the nematodes with a microbe-based nematicidal composition that has been prepared by cultivating a microorganism under conditions such that the microorganism produces a biosurfactant , wherein said nematicidal composition comprises the microorganism and/or broth in which the microorganism is cultivated.2. The method claim 1 , according to claim 1 , wherein the biosurfactant is a glycolipid.3. The method claim 2 , according to claim 2 , wherein the glycolipid is a sophorolipid (SLP).4. The method claim 2 , according to claim 2 , wherein the glycolipid is a mannosylerytrithol lipid (MEL).5Starmerella, PichiaPseudozyma.. The method claim 1 , according to claim 1 , wherein the microorganism is a fungus selected from and6Starmerella bombicola.. The method claim 5 , according to claim 5 , wherein the fungus is7Pseudozyma aphidis.. The method claim 5 , according to claim 5 , wherein the fungus is8Pichia anomalaWickerhamomyces anomalus. The method claim 5 , according to claim 5 , wherein the fungus is ().9. The method claim 1 , according to claim 1 , wherein the broth is applied to nematodes claim 1 , and/or their environment claim 1 , without first separating biosurfactant from cell mass.10Meloidogyne incognitalBelonolaimus longicaudatusHeterodera glycinesPratylenchusXiphinemaTylenchulus semipenetrans. The method claim 1 , according to claim 1 , used to control a nematode selected from root-knot nematode () claim 1 , sting nematode () claim 1 , soybean cyst nematode () claim 1 , lesion nematode (sp.) claim 1 , dagger nematode (sp.) claim 1 , and citrus nematode ().11. The method claim 1 , according to claim 1 , wherein said method is used to control nematode pests of plants.12. The method claim 11 , according to claim 11 , ...

METHOD FOR THE REGIOSELECTIVE DEACETYLATION OF MANNOSYLERYTHRITOL LIPIDS

The present invention relates to methods for the enzymatic deacetylation of mannosylerythritol lipids produced by fermentation using lipases. More in particular, the present invention relates to a method for the enzymatic deacetylation of mannosylerythritol lipids using a hydrolyzing enzyme in an organic solvent containing only low amounts of water, preferably, no water. It further provides the use of organic solvents, containing only low amounts of water, more preferably, no water, for the enzymatic deacetylation of mannosylerythritol lipids. 6. The method according to ; wherein the C2-C8 alcohol is selected from the group consisting of linear and branched C2-C8 alcohols.7. The method according to claim 1 , wherein the organic solvent contains less than 9% water.8. The method according to claim 1 , wherein the organic solvent contains no additional water.9. The method according to claim 1 , wherein the hydrolyzing enzyme is a lipase.10. (canceled)11. The method according to ; wherein the C2-C8 alcohol is selected from the group consisting of ethanol claim 1 , 1-propanol claim 1 , 1-butanol claim 1 , 1-pentanol claim 1 , 1-hexanol claim 1 , 1-heptanol claim 1 , 1-octanol claim 1 , isopropanol claim 1 , isobutanol claim 1 , t-butanol claim 1 , 2-pentanol claim 1 , isoamyl alcohol claim 1 , 2-ethylhexanol claim 1 , cyclohexanol claim 1 , and benzylalchohol.12. The method according to claim 1 , wherein the organic solvent contains less than 3% water.1314.-. (canceled)15Candida antarctica. The method as defined in claim 9 , wherein the lipase is a lipase B. The present invention relates to methods for the enzymatic deacetylation of mannosylerythritol lipids produced by fermentation. More in particular, the present invention relates to a method for the enzymatic deacetylation of mannosylerythritol lipids using a lipase in an organic solvent containing only low amounts of water, preferably, no water. It further provides the use of organic solvents, containing only low ...

ENHANCED PRODUCTION OF RHAMNOLIPIDS USING AT LEAST TWO CARBON SOURCES

Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source. 1. A semi-continuous method for producing a plurality of fermentations comprising one or more rhamnolipids (RL) comprising:(a) culturing a rhamnolipid producing microorganism in culture medium comprising at least two carbon sources, wherein at least one carbon source is a sweetener and at least one carbon source is an oil containing medium or long chain triglycerides, at least one nitrogen source, at least one phosphorous source, at least one magnesium source, at least one potassium source, at least one sulfur source, at least one chloride source, and at least one sodium source and optionally in the presence of an emulsifier for at least about 1 day to obtain a first fermentation medium comprising rhamnolipid comprising one or more rhamnolipids (RL) and at least one rhamnolipid producing microorganism;(b) removing at least about 70% of said first fermentation medium obtained in step (a);(c) replacing said first fermentation medium removed in (b) with culture medium having the composition set forth in step (a);(d) repeating steps (a)-(c) at least one time to obtain a subsequent fermentation medium comprising rhamnolipids and at least one rhamnolipid producing microorganisms.2. The method according to claim 1 , wherein said method yields RL at a rateof at least about 1.7 g RL/L/h.3. The method according to claim 1 , wherein said method yields at least about 40 g RL/L.4. The method according to claim 1 , wherein said rhamnolipid producing microorganism is cultured in step (a) for about 1 to about 4 days.5. The method according to claim 1 , which further comprises adding a composition comprising one or more micronutrients at a concentration of no more than 20 mg/L of micronutrient solution to said culture medium in step (a) at 0.1% v/v of total fermentation volume per day.6. The method according to claim 1 ...

SOPHOROLIPID-CONTAINING COMPOSITIONS

A process to produce a sophorolipid composition is disclosed, the steps including obtaining a sophorolipid containing composition having a pH of less than 5, adding 6 percent by weight or less of a free fatty acid to the composition, and thereafter adjusting the pH of the composition to a pH greater than 5. In some embodiments, the sophorolipid composition initially comprises from 4 to 80 percent by weight dry solids. 1. A process to produce a sophorolipid composition , the process comprising:(a) obtaining a sophorolipid containing composition comprising about 4-80 percent by weight total dry solids, comprising at least one sophorolipid, wherein the sophorolipid containing solution exhibits a pH of less than 5,(b) adding about 6 percent by weight or less of a least one free fatty acid to the sophorolipid containing composition to provide a fatty acid adjusted sophorolipid composition, and(c) adjusting the pH of the fatty acid adjusted sophorolipid composition to a pH greater than 5 to provide the sophorolipid composition.2. The process of claim 1 , wherein the total dry solids of (a) comprises from about 40 to about 99 percent by weight total sophorolipids based on the total dry solids.39-. (canceled)10. The process of claim 13 , wherein the sophorolipid containing composition of (a) comprises less than 75 percent by weight water.1112-. (canceled)13. The process of claim 1 , wherein the sophorolipid containing composition of (a) comprises 25-96 percent by weight water.13. (canceled)14. The process of claim 1 , wherein separating the sophorolipid layer from an aqueous layer comprises heating a fermentation broth containing sophorolipid to a temperature of about 70-75° C. to provide a heated broth claim 1 , cooling the heated broth to an ambient temperature claim 1 , and decanting a higher density sophorolipid layer from a lower density aqueous layer.15. The process of claim 1 , wherein the at least one sophorolipid comprises ester-form sophorolipid and acidic-form ...

AMPHOTERIC GLYCOLIPID BIOSURFACTANT AND ITS PREPARATION METHOD

Provided herein are amphoteric glycolipid biosurfactants containing an amphoteric glycolipid biological surface active molecule preparation produced by acid precipitation of culture supernatant produced by sequentially culturing , and , for instance in a fermentation medium comprising a hydrophilic carbon source and a hydrophobic carbon source. Also described are amphoteric glycolipid biological surface active molecule preparations, and methods of making such preparations. The amphoteric molecules have anionic and cationic groups; example molecules include 17-L-[(2′-O-β-D-glucopyranosyl-β-D-Glucosyl)-O-]-octadecenoic acid amine-6′,6″ diacetate, and 17-L-[(2′-O-β-D-glucopyranosamine-β-D-rhamnosyl)-O-]-octadecenoic acid-6′,6″ diacetate. The amphoteric glycolipid biosurfactant has good compatibility with other types of surfactants, high temperature resistance and salt resistance, and is suitable for use in a variety of liquid systems. 2. The amphoteric glycolipid biosurfactant of claim 1 , comprising:0.5-3.0% fatty acids,0.1-1.0% polysaccharide,20.0-40.0% amphoteric glycolipid biological surface active molecule preparation,0.1%-0.5% glycosamine,0.01-0.2% lipopeptide,1-3% ethanol, and0.1-0.5% fatty amine.3. The amphoteric glycolipid biosurfactant of claim 1 , wherein the polysaccharide:comprises a polysaccharide polymer comprising one or more of rhamnose, mannose, or glucose; andhas a molecular weight greater than 200,000 Daltons.4. The amphoteric glycolipid biosurfactant of claim 1 , wherein the fatty acid comprises a C-Clong-chain fatty acid.5. The amphoteric glycolipid biosurfactant of claim 1 , wherein the sugar amine comprises N-acetylglycosamine of glucose with a molecular weight of less than 1000 Daltons.6. The amphoteric glycolipid biosurfactant of claim 1 , wherein the lipopeptides comprise at least one lipopeptide containing 7-14 amino acid chains claim 1 , with a molecular weight of 800-3000 Daltons.7. The amphoteric glycolipid biosurfactant of claim 6 , ...

PROCESS FOR PRODUCTION OF A SOLID MATERIAL CONTAINING ISOMALTULOSE CRYSTALS AND TREHALULOSE

The present invention provides a process for production of a solid material containing isomaltulose crystals and trehalulose comprising the process steps A) bringing an enzyme complex which is able to catalyse the reaction of sucrose to isomaltulose and trehalulose into contact with a sucrose-containing solution; B) isomerizing at least some of the sucrose to isomaltulose and trehalulose; C) separating off the enzyme complex to give a solution containing isomaltulose, trehalulose and water; D) partial removal of the water by evaporation, while obtaining a concentrated solution with, based on the total solution, a solid content of 75 wt % to 95 wt %, preferably 80 wt % to 93 wt %, particularly preferably 86 wt % to 92 wt %; E) bringing the concentrated solution to a temperature of 30° C. to 63° C., preferably 45° C. to 62° C., even more preferably 55° C. to 60° C., and subsequent induction of isomaltulose crystallisation in this temperature range followed by cooling while obtaining a solid material containing isomaltulose crystals and trehalulose. 1. A process for production of a solid material comprising isomaltulose crystals and trehalulose , the process comprising:A) bringing an enzyme complex which is able to catalyse a reaction of sucrose to isomaltulose and trehalulose into contact with a sucrose-comprising solution;B) isomerizing at least some of the sucrose in the sucrose-comprising solution to isomaltulose and trehalulose;C) separating off the enzyme complex, to obtain a solution comprising isomaltulose, trehalulose and water;D) partially removing the water by evaporation, to obtain a concentrated solution with a solid content of 75 wt % to 95 wt %, based on a total weight of the concentrated solution;E) bringing the concentrated solution to a temperature of 30° C. to 63° C., and subsequent induction of isomaltulose crystallization in this temperature range followed by cooling, to obtain a solid material comprising isomaltulose crystals and trehalulose.2. ...

PRODUCTION OF FERMENTATION PRODUCTS CONTAINING RHAMNOLIPIDS

In various aspects, the present invention is directed to a scalable method of producing rhamnolipids by bacterial fermentation with higher product concentrations, yields and productivities and preventing excessive foaming during the cell growth phase when the cell respiration rate is higher. It has been found that by slowing the growth rate of the bacteria by altering the ratio of the nitrogen source to the non-nitrogen source in the initial fermentation medium and supplementing the nitrogen source, excessive foaming in the growth phase can be prevented. Further, by using the non-nitrogen source as the limiting nutrient that initiates the stationary phase and then supplementing fermentation broth with the nitrogen and carbon sources, the length of the standing phase, and with it the time during which rhamnolipid production occurs can be greatly extended. 1. A method for improving production rates , conversions and concentrations of rhamnolipids during fermentation-based rhamnolipid production comprising:A) growing a rhamnolipid producing bacteria in a fermentation broth comprising at least one carbon source, at least one nitrogen source and a non-nitrogen source; andB) after the growth of said rhamnolipid producing bacteria is substantially complete, adding one or more additional quantities of a nitrogen source to the fermentation broth to maintain a substantially non-decreasing rate of rhamnolipids production.2Pseudomonas aeruginosa.. The method of wherein the rhamnolipid producing bacteria is3. The method of wherein the step of growing (step A) further comprises:1) determining a quantity of each one of said at least one carbon source, at least one nitrogen source, and non-nitrogen source necessary to grow said rhamnolipid producing bacteria to a desired cell concentration;2) forming an initial fermentation medium comprising some or all of said quantity of the at least one carbon source necessary to grow said rhamnolipid producing bacteria to the desired cell ...

CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids. 1. (canceled)2. An isolated or purified sophorolipid-producing cell transformed with a nucleic acid encoding:{'sub': '1', '(a) an Epolypeptide comprising SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63; or'}(b) a polypeptide which catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid, wherein said polypeptide comprises a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion;{'sub': 2', '3', '4', '5', '3', '4, 'wherein said cell may optionally contain a nucleic acid encoding at least one E, E, Eor Epolypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an Eand/or Epolypeptide;'}wherein{'sub': 2', '2, 'Ecomprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 8 or 11 have been modified by deletion, substitution, and/or insertion, wherein the Epolypeptide catalyzes the conversion of UDP-glucose and 17-hydroxy-Z-9-octadecenoic acid into 17-(β-D-glucopyranosyloxy)-Z-9-octadecenoic acid;'}{'sub': 3', '3, 'Ecomprises (a) the amino acid sequence selected of SEQ ID NO: 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 11 which is identical to the amino acid sequence of SEQ ID NO: 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 11 have been modified by deletion, substitution, and/or insertion, ...

CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids. 1. (canceled)2. An isolated or purified sophorolipid-producing cell:(i) transformed with a nucleic acid encoding an E3 polypeptide; or{'sub': '3', '(ii) modified to disrupt at least one endogenous gene encoding an Epolypeptide;'}{'sub': '3', 'wherein said E3 polypeptide comprises (a) an Epolypeptide of SEQ ID NO: 11; or (b) an E3 polypeptide that catalyzes the conversion of 17-(β-D-glucopyranosyloxy)-Z-9-octadecenoic acid and UDP-glucose into 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid, wherein said polypeptide comprises a variant of the amino acid sequence of SEQ ID NO: 11 which is identical to SEQ ID NO: 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 11 have been modified by deletion, substitution, and/or insertion;'}{'sub': 1', '2', '4', '5', '3', '4, 'wherein said cell may optionally contain a nucleic acid encoding at least one E, E, Eor Epolypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an Eand/or Epolypeptide; wherein{'sub': '1', 'Ecomprises (a) a polypeptide of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion; and catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid;'}{'sub': 2', '2, 'Ecomprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one ...

Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids. 1. (canceled)2. An isolated or purified sophorolipid-producing cell: [{'sub': 5', '5, 'wherein Ecomprises (a) the amino acid sequence of SEQ ID NO: 10; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 10 which is identical to the amino acid sequence of SEQ ID NO: 10 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 10 have been modified by deletion, substitution, and/or insertion, wherein the Epolypeptide has the ability to transfer a sophorolipid out of the sophorolipid-producing cell into the surrounding medium;'}, {'sub': 1', '2', '3', '4', '3', '4, 'wherein said cell may optionally contain a nucleic acid encoding at least one E, E, Eor Epolypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an Eand/or Epolypeptide; wherein, {'sub': '1', 'Ecomprises (a) a polypeptide of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion; and catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid;'}, {'sub': 2', '2, 'Ecomprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 8 or 11 have been modified by deletion, substitution, and/or insertion, wherein the Epolypeptide catalyzes the conversion of UDP-glucose and 17-hydroxy-Z-9-octadecenoic ...

METHODS OF GANGLIOSIDE PRODUCTION

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g. GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO) cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. The method of claim 5 , wherein said fibroblast cell is a fibroblast from a human with GM1 gangliosidosis.8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

Sophorolipid Highly-Productive Mutant Strain

Provided is a microorganism exhibiting high production capability for sophorolipids. Disclosed is a yeast mutant strain having high sophorolipid productivity, in which a transporter transporting Acyl-CoA to a peroxisome has been deleted or deactivated. 1. A sophorolipid-producing yeast mutant strain , in which a transporter transporting Acyl-CoA to a peroxisome has been deleted or deactivated.2. The mutant strain according to claim 1 , wherein the transporter transporting Acyl-CoA to a peroxisome is PXA1 claim 1 , PXA2 claim 1 , or a protein equivalent thereto.3. The mutant strain according to claim 2 , whereinthe PXA1 is a protein consisting of the amino acid sequence set forth in SEQ ID NO:2,the PXA2 is a protein consisting of the amino acid sequence set forth in SEQ ID NO:4,the protein equivalent to PXA1 is a protein consisting of an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:2, and forming a heterodimer together with PXA2 or a protein equivalent thereto to work as a transporter transporting Acyl-CoA to a peroxisome, andthe protein equivalent to PXA2 is a protein consisting of an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:4, and forming a heterodimer together with PXA1 or a protein equivalent thereto to work as a transporter transporting Acyl-CoA to a peroxisome.4. The mutant strain according to claim 2 , wherein PXA1 gene claim 2 , PXA2 gene claim 2 , or a gene equivalent thereto has been deleted or deactivated.5. The mutant strain according to claim 4 , whereinthe PXA1 gene is a gene encoding a protein consisting of the amino acid sequence set forth in SEQ ID NO:2,the PXA2 gene is a gene encoding a protein consisting of the amino acid sequence set forth in SEQ ID NO:4,the gene equivalent to PXA1 gene is a gene encoding a protein that forms a heterodimer together with PXA2 or a protein equivalent thereto to work as a transporter transporting Acyl- ...

IDENTIFICATION AND CHARACTERIZATION OF UDP-GLUCOSE:PHLORETIN 4'-O-GLUCOSYLTRANSFERASE FROM MALUS X DOMESTICA BORKH

A method of producing trilobatin is disclosed. The method comprising contacting a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity with phloretin and UDP-glucose under conditions which allow the formation of trilobatin, thereby producing trilobatin. A method of producing a plant which produces trilobatin, transgenic plant or plant cell and methods of producing transgenic plants are disclosed. Composition comprising trilobatin are also disclosed. 1. A method of producing trilobatin , the method comprising contacting a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity with phloretin and UDP-glucose under conditions which allow the formation of trilobatin , thereby producing trilobatin.2. The method of claim 1 , being effected in vivo.3. The method of claim 2 , wherein said in vivo is in a plant cell.47-. (canceled)8. The method of claim 1 , further comprising purifying said trilobatin.9. A method of producing a plant which produces trilobatin claim 1 , the method comprising upregulating in the plant expression of a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity claim 1 , and wherein said plant comprises phloretin and UDP-glucose claim 1 , thereby producing the plant.10. The method of claim 9 , wherein said upregulating comprises genetic engineering.11. (canceled)12. A transgenic plant or plant cell comprising an exogenous nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity.13. A method of producing the transgenic plant of claim 12 , the method comprising introducing into a cell of the plant a nucleic acid construct comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at ...

TRANS-RESVERATROL POLYSACCHARIDE, METHOD OF PRODUCING THE SAME, AND COMPOSITION COMPRISING THE SAME

An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. Another object of the present invention is to provide a trans-resveratrol derivative that has no toxicity against cells and has sufficient antioxidative properties and/or a sufficient whitening effect. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin glucanotransferase. 113-. (canceled)16. The method of wherein the skin is the skin of the scalp.17. The method of wherein the skin is the skin of the scalp.18. The method of wherein the compound of formula (7) and the compound of formula (1) are formulated in a single composition.19. The method of wherein the compound of formula (7) and the compound of formula (1) are formulated in separate compositions. The present invention relates to trans-resveratrol polysaccharide, a method for producing the same, a liposome comprising the same, and a composition comprising the same.It is widely known that resveratrol exhibits antioxidative properties, such as protection from cell death induced by hydrogen peroxide, etc., in the body. However, resveratrol is poorly soluble in water, and monosaccharide glycosides of resveratrol, which have improved water solubility, are known.Further, as shown in PTL 1, a technique using cyclodextrin glucanotransferase has been developed as a technique for producing polysaccharides of polyphenols.Moreover, it has been revealed that trans-resveratrol has the effects of inducing NFκB activation, etc., but cis-resveratrol does not have such effects (NPL 1).The present inventors found that monosaccharide glycosides of trans-resveratrol underwent cis-trans isomerization, thereby resulting in the isomerization of about 15% of the trans-form to the cis-form.Moreover, as shown in NPL 1, since cis-resveratrol is ...

RHAMNOLIPID SYNTHESIS

There is provided a method of producing at least one rhamnolipid comprising: 111-. (canceled)13. The method of claim 12 , wherein said organic radicals are alkyl radicals that are optionally branched claim 12 , optionally substituted claim 12 , and optionally unsaturated.14. The method of claim 13 , wherein at least one alkyl radical is hydroxy-substituted.15. The method of claim 13 , wherein at least one alkyl radical is mono- claim 13 , di- or tri-unsaturated.16. The method of claim 12 , wherein said identical or different organic radicals comprise 5 to 13 carbon atoms.17. The method of claim 12 , wherein said carbon source is an alkane selected from the group consisting of: hexane; heptane; octane; nonane; and decane; and/or an alkanoic acid selected from the group consisting of: hexanoic acid; haptanoic acid; octanoic acid; nonanoic acid; and decanoic acid.18. The method of claim 12 , wherein the recombinant cell has been genetically modified such that claim 12 , compared to the wild-type cell claim 12 , the recombinant cell has an increased activity of enzyme E claim 12 , wherein Eis an oxidoreductase.19. The method according to claim 18 , wherein the oxidoreductase is selected from the group consisting of: alkB-type oxidoreductase; monooxygenase; and NAD(P)H dependent alcohol dehydrogenase (ADH).20. The method of claim 19 , wherein the carbon source is hexane and/or decane.21. The method of claim 12 , wherein at least 40% by weight of the total carbon content in the medium is hexane claim 12 , decane claim 12 , hexanoic acid and/or decanoic acid.22. The method of claim 12 , wherein:{'sub': '1', 'a) enzyme Eis able to catalyse the conversion of 3-hydroxyalkanoyl-ACP via 3-hydroxyalkanoyl-3-hydroxyalkanoic acid-ACP to hydroxyalkanoyl-3-hydroxyalkanoic acid;'}{'sub': '2', 'b) enzyme Eis able to catalyse the conversion of dTDP-rhamnose and 3-hydroxyalkanoyl-3-hydroxyalkanoate to α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate; and'}{'sub': '3', 'c) enzyme ...

Compound Amycolamicin, Method for Producing the Same, and Use of the Same

A compound having a structure expressed by the following Structural Formula (1), tautomers thereof, or salts of the compound or the tautomers. 3Amycolatopsis. The method according to claim 2 , wherein the microorganism is a microorganism of sp. MK575-fF5 strain deposited under accession number FERM P-21465.5Amycolatopsis. The microorganism according to claim 4 , wherein the microorganism is a microorganism of sp. MK575-fF5 strain deposited under accession number FERM P-21465. This is a continuation application of PCT/JP2009/058210, filed on Apr. 24, 2009.1. Field of the InventionThe present invention relates to a new compound having an excellent antibacterial activity against a wide variety of pathogenic bacteria such as drug-resistant bacteria and bacteria causing pneumonia in domestic livestock, a method for producing the new compound, use of the new compound, and a new microorganism that produces the new compound.2. Description of the Related ArtIn general, infectious diseases caused by pathogenic bacteria are treated with chemotherapy including administering drugs such as antibiotics. However, conventionally, frequent use of such drugs has allowed pathogenic bacteria to acquire an ability to neutralize these drugs, leading to appearance of resistant bacteria to which the drugs are ineffective. Actually, many drug-resistant bacteria have been problematic mainly in medical facilities.For example, as one clinically important problem, , which is known as bacteria causing suppurative diseases, pneumonia and food poisoning, acquires multidrug resistances to methicillin or other antibiotics to be methicilline-resistant (MRSA). At present, vancomycin, teicoplanin, arbekacin, line zolid, etc. are used as typical therapeutic drugs against MRSA. However, it is generally difficult to completely eliminate MRSA. In particular, thorough care should be taken about the use of vancomycin, since appearance of vancomycin resistant (VRSA) has already been reported (see Sievert D M, ...

Method for preparing rhamnolipids

The present disclosure relates to a method for producing rhamnolipids.

CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION

The invention provides novel carbohydrate esters, in particular disaccharide esters, and the methods of their preparation. These compounds find use as microbial media components for the induction of gene expression in microbial fermentation processes. 2. The method according to claim 1 , wherein an optional conventional inducer is added to the culture.3. The method according to claim 2 , wherein the optional conventional inducer comprises lactose claim 2 , cellobiose claim 2 , sophorose claim 2 , cellulose claim 2 , cellulose hydrolysate claim 2 , maltose claim 2 , isomaltose claim 2 , maltodextrins claim 2 , starch claim 2 , or starch hydrolysate.4. The method according to claim 1 , wherein the protein of interest is cellulase or amylase.5. The method according to claim 1 , wherein the protein of interest is a homologous or heterologous protein.6. The method according to claim 5 , wherein the homologous or heterologous protein is an enzyme claim 5 , a hormone claim 5 , a growth factor claim 5 , a cytokine or an antibody.7. The method according to claim 1 , wherein the fermentation host is capable of producing cellulase or amylase.8Trichoderma, Humicola, Pleurotus, Fusarium, Aspergillus, Streptomyces, Thermomonospora, Bacillus, Cellulomonas, Penicillium, Basidiomycete, Chrysoporium, Pestalotiopsis, Neurospora, Cephalosporium, Achlya, Podospora, Endothia, Mucor, Cochliobolus, Myceliopthora, TalaromycesPyricularia.. The method according to claim 1 , wherein the fermentation host is a filamentous fungus or bacteria or other hosts selected from the genus group consisting of claim 1 , and9Trichoderma reeseiAspergillus niger.. The method according to claim 1 , wherein the fermentation host is the filamentous fungus or10. The method according to claim 1 , wherein the fermentation host is grown in a liquid culture or on a solid substrate without free-flowing liquid.11. The method according to claim 1 , wherein the fermentation host has a promoter operably linked to a gene ...

Maltobionate As Antioxidant in Food Products

Maltobionate has an antioxidative effect in food and feed products. The antioxidant can be produced directly from starch or maltose already present in the food product, using enzymatic catalyzed processes. The antioxidant production can be performed on an isolated fraction of a food product from which it can be added back to the food production process or the final food product. Alternatively, the antioxidant can be produced as an integrated part of the food production process by adding the relevant enzymes to the process.

Biosynthetic production of steviol glycosides and processes therefore

The present invention relates to the production of steviol glycoside rebaudiosides D4, WB1 and WB2 and the production of rebaudioside M from Reb D4.

Modified Plants for Producing Aroma/Fine/Specialty Chemicals

The present disclosure describes genetically modified plants that contain one or more exogenous genes associated with aroma/fine/specialty compound biosynthesis, which are capable of producing aroma/fine/specialty compounds. 182-. (canceled)83. A modified plant comprising one or more exogenous polynucleotides encoding one or more enzymes associated with an aroma compound biosynthesis , a fine compound biosynthesis , a specialty compound biosynthesis or a combination thereof.84. The modified plant of claim 83 , wherein the one or more enzymes is a synthase claim 83 , a reductase claim 83 , a transferase claim 83 , or a combination thereof.85. The modified plant of claim 84 , whereinthe synthase is a phenylacetaldehyde synthase, a propenylphenol synthase, an allylphenol synthase, a biologically active fragment or variant thereof or a combination thereof;the reductase is a phenylacetaldehyde reductase or a biologically active fragment or variant thereof; andthe transferase is an acyl transferase or a biologically active fragment or variant thereof86Larrea tridentateLarrea tridentata. The modified plant of claim 85 , wherein the propenyl phenol synthase is propenylphenol synthase or a biologically active fragment or variant thereof and the allylphenol synthase is allylphenol synthase or a biologically active fragment or variant thereof.87. The modified plant of claim 83 , wherein the aroma compounds include at least one or more metabolites associated with 2-phenyl ethanol synthesis.88. The modified plant of claim 83 , wherein the modified plant produces a 2-phenyl ethanol claim 83 , an allyl phenol claim 83 , a propenyl phenol or a combination thereof.89. The modified plant of claim 83 , wherein the modified plant is selected from the group consisting of a poplar claim 83 , a poplar hybrid claim 83 , an aspen claim 83 , and a red alder.90. The modified plant of claim 83 , wherein the modified plant produces aroma compounds that are sequestered in the modified plant as ...

MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF

The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes. 111-. (canceled)12. A method of synthesizing a moenomycin , a moenomycin derivative , or a moenomycin intermediate wholly or partially in vitro comprising: reacting a one or more moenomycin precursor , derivative and/or moenomycin intermediate with a one or more polypeptide selected from the group consisting of: moeA4 , moeB4 , moeC4 , moeB5 , moe A5 , moeD5 , moeJ5 , moeE5 , moeF5 , moeH5 , moeK5 , moeM5 , moeN5 , moe05 , moeX5 , moeP5 , moeR5 , moeS5 , moeGT1 , moeGT2 , moeGT3 , moeGT4 , and moeGT5 , under conditions wherein the moenomycin , the moenomycin derivative , or the intermediate is wholly or partially synthesized.13. A method of modifying a moenomycin wholly or partially in vitro comprising: reacting a moenomycin , a moenomycin derivative or a moe intermediate with a one or more polypeptide selected from the group consisting of: moeA4 , moeB4 , moeC4 , moeB5 , moe A5 , moeD5 , moeJ5 , moeE5 , moeF5 , moeH5 , moeK5 , moeM5 , moeN5 , moeO5 , moeX5 , moeP5 , moeR5 , moeS5 , moeGT1 , moeGT2 , moeGT3 , moeGT4 , and moeGT5 , under conditions wherein the moenomycin , the moenomycin derivative , or the moenomycin intermediate is modified.1415-. (canceled)17. The moenomycin derivative of claim 16 , wherein R and Rindependently are —NH.19. (canceled)2122-. (canceled)24. The moenomycin derivative of claim 23 , wherein R3 is hydrogen or hydroxyl.25. (canceled)2728-. (canceled)3031-. (canceled)3334-. (canceled)3637-. (canceled)3943-. (canceled)44. A pharmaceutical composition comprising the moenomycin derivative of and a pharmaceutically acceptable carrier.4648-. (canceled)49. A ...

VACCINE COMPOSITIONS AGAINST PATHOGENIC FUNGI AND METHODS FOR USE THEREOF

The present disclosure provides compositions comprising mutant fungi include an inactive form of the sterylglucosidase enzyme. The present disclosure is also directed to vaccine based compositions, which include a mutant fungus that prohibit pathogenic fungal infection. This disclosure also provides methods for administering these compositions as a prophylaxis against fungal infection, as well as methods for isolating sterylglucosides that include the use of such mutant fungal compositions. 1. A composition comprising a mutant fungus , wherein said mutant fungus comprises an inactivated Sterylglucosidase (Sgl1) gene or homolog thereof.2. The composition of claim 1 , wherein said mutant fungus lacks the ability to metabolize sterylglucosides (SGs).3. The composition of claim 1 , wherein said mutant fungus accumulates sterol glycosides.4. The composition of claim 1 , wherein said mutant fungus is avirulent.5Cryptococcus. The composition of claim 1 , wherein said mutant fungus is from a genus.6Cryptococcus neoformans, Cryptococcus gatii, Cryptococcus albidus, Cryptococcus uniguttulatus, Candida albicans, Aspergillus fumigatus. The composition of claim 1 , wherein said mutant fungus is selected from the group consisting of and other fungi in which the Sgl1 gene is deleted.7. A method for producing sterylglucosides comprising:providing a mutant fungus comprising an inactivated Sterylglucosidase (Sgl1) gene or homolog thereof;expressing said mutant fungus in a fungal cell, wherein said fungal cell produces sterylglucosides; andisolating said sterylgucosides.8. The method of claim 7 , wherein said mutant fungus lacks the ability to metabolize sterylglucosides (SGs).9. The method of claim 7 , wherein said mutant fungus accumulates sterol glycosides.10Cryptococcus. The method of claim 7 , wherein said mutant fungus is from a genus.11Cryptococcus neoformans, Cryptococcus gatii, Cryptococcus albidus, Cryptococcus uniguttulatus, Candida albicans, Aspergillus fumigatus. The ...

Use of ginsenoside m1 for inhibiting renal fibrosis

The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.

Polyphenol, terpenoid, glycoside, and alkaloid production by crocus sativus cell cultures

A method for producing metabolites of Crocus sativus ( C. sativus ) includes (i) selecting a cell line of C. sativus that produces one or more saffron metabolites in cell suspension culture, and (ii) growing the selected cell line in a suspension cell culture to produce the saffron metabolite.

HIGH-PURITY RUBUSOSIDE AND PROCESS FOR PRODUCING OF THE SAME

The invention provides a process of producing Rubusoside from steviol glycosides of plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. 1Stevia rebaudiana. A process for preparing Rubusoside from steviol glycosides of comprising the steps of:a. providing a solution comprising Stevioside;b. providing an enzyme composition comprising at least one enzyme selected from the group comprising rhamnosidase, β-glucosidase, β-glucanase, hesperidinase, naringinase, pectinase, cellulase, hemicellulase, xylanase;c. adding the enzyme composition to the solution comprising Stevioside to obtain reaction mixture;d. incubating the reaction mixture to facilitate complete or partial transformation of Stevioside to Rubusoside;e. recovering and purifying high purity Rubusoside from reaction mixture.2. A process of wherein step (a) the concentration of Stevioside is 1-50% (wt/vol) claim 1 , preferably 5-30% (wt/vol) claim 1 , more preferably 8-10% (wt/vol).3. A process of wherein step (d) the molar yield of Rubusoside from Stevioside is 1-100% claim 1 , preferably 80-100% and more preferably 95-100%.4. A process of wherein step (e) at least one purification techniques is employed selected from the group comprising ion exchange treatment claim 1 , macroporous adsorbent treatment claim 1 , membrane process claim 1 , chromatographic separation claim 1 , and crystallization from various solvent systems.5. A process of wherein step (e) the recovery and purification of Rubusoside comprises the steps of:a. providing reaction mixture containing Rubusoside;b. contacting the reaction mixture ...

Methods of Producing Rhamnolipids

The present invention relates to a method of preparing at least one rhamnolipid comprising: 115-. (canceled)17. The method of claim 16 , wherein the Cmolecule is selected from the group consisting of: butane; 1-butanol; 2-butanol; 1-butanal; butanone; butyric acid; and combinations thereof.18. The method of claim 16 , wherein the cell has been genetically modified such that claim 16 , compared to the wild-type of the cell claim 16 , the cell has an increased activity of an oxidoreductase.19. The method of claim 18 , wherein the oxidoreductase is selected from the group consisting of: alkB-type oxidoreductase; monooxygenase; and NAD(P)H dependent alcohol dehydrogenase (ADH).20. The method of claim 16 , wherein the recombinant cell has an increased activity of the enzymes E1 claim 16 , E2 claim 16 , E3 and oxidoreductase compared to the wild-type of the cell and wherein the C4 molecule is butane.21. The method of claim 16 , wherein said recombinant cell is in a medium in which at least 40% by weight of the total carbon content of the medium is C4 molecules.22. The method of claim 16 , wherein:{'sub': '1', 'a) the enzyme Eis able to catalyze the conversion of 3-hydroxyalkanoyl-ACP via 3-hydroxyalkanoyl-3-hydroxyalkanoic acid-ACP to hydroxyalkanoyl-3-hydroxyalkanoic acid;'}{'sub': '2', 'b) the enzyme Eis able to catalyze the conversion of dTDP-rhamnose and 3-hydroxyalkanoyl-3-hydroxyalkanoate to α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate; and'}{'sub': '3', 'c) the enzyme Eis able to catalyze the conversion of dTDP-rhamnose and α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate to α-L-rhamnopyranosyl-(1-2)-α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.'}24Aspergillus; Corynebacterium; Brevibacterium; Bacillus; Acinetobacter; Alcaligenes; Lactobacillus; Paracoccus; Lactococcus; Candida; Pichia; Hansenula; Kluyveromyces; Saccharomyces; Escherichia; Zymomonas; Yarrowia; Methylobacterium; Ralstonia; Pseudomonas; Rhodospirillum; Rhodobacter; ...

Process for producing a particulate composition comprising anhydrous crystalline 2-o-alpha-d-glucosyl-l-ascorbic acid

The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside.

Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation

Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. 1. A process of making an activated polysialic acid (PSA) molecule comprising a terminal sialic acid unit at the reducing end , the process comprising:a) reducing the reducing terminal sialic acid unit to form a vicinal diol group;b) selectively oxidizing the vicinal diol group of step (a) to form an aldehyde group;c) aminating the aldehyde group of step (b) to form an amine group; andd) reacting the amine group of step (c) with a bifunctional reagent comprising two amine-reactive functional groups to form an activated PSA molecule, the activated PSA molecule being monofunctional and comprising an amine-reactive group at the reducing end.2. The process of claim 1 , wherein the PSA molecule includes PSA molecules consisting substantially only of units of sialic acid or PSA molecules comprising sialic acid units alternating with other saccharide unit.3. The process of claim 2 , wherein the PSA molecules consisting substantially only of units of sialic acid alpha-2 claim 2 ,8 PSA molecules and/or alpha-2 claim 2 ,9 linked PSA molecules.4. The process of claim 1 , wherein the PSA molecule comprises at least 5 sialic acid units.5. The process of claim 4 , wherein the PSA molecule comprises at least 10 sialic acid units.6. The process of claim 5 , wherein the PSA molecule comprises at least 50 sialic acid units.7. The process of claim 1 , wherein in step (a) the reducing agent used is a hydrite or hydrogen with catalysts.8. The process of claim 7 , wherein the hydrite is an alkali metal hydride.9. The process of claim 1 , wherein ...

PRODUCTION OF DIRHAMNOSE-LIPID IN RECOMBINANT NONPATHOGENIC BACTERIUM PSEUDOMONAS CHLORORAPHIS

NRRL B-30761 produces monorhamnolipids with predominantly 3-hydroxydodecenoyl-3-hydroxydecanoate (C-C) or 3-hydroxydodecanoyl-3-hydroxydecanoate (C-C) as the lipid moiety under static growth conditions. The cloning and sequencing of three genes and proteins involved in the biosynthesis of monorhamnose-lipid (RL) is described. Expression of two of these genes, i.e., rhlA and rhlB, together in NRRL B-30761 increases RL production by at least 10-fold. Also the generation of a recombinant NRRL B-30761 capable of synthesizing dirhamnose-lipid (RL) is described. Characterization of RL and RL produced by the recombinant NRRL B-30761 is also described. 166-. (canceled)67Pseudomonas. A recombinant Pseudomonas chlororaphis comprising an expression vector , wherein said expression vector further comprises a promoter operably linked to a heterologous polynucleotide encoding rhamnosyltransferase C.68Pseudomonas chlororaphisPseudomonas. The recombinant of wherein said rhamnosyltransferase C has the amino acid sequence of SEQ ID NO: 26.69Pseudomonas chlororaphisPseudomonas. The recombinant of wherein said rhamnosyltransferase C has the nucleotide sequence of SEQ ID NO: 25.70Pseudomonas chlororaphisPseudomonas chlororaphisP. chlororaphis. The recombinant of wherein said is NRRL B-30761.71. A method of producing dirhamnose-lipid comprising{'i': Pseudomonas chlororaphis', 'Pseudomonas rhamnosyltransferase', 'P. chlororaphis,', 'P. chlororaphis, 'transforming a wild-type with an expression vector comprising a promoter operably linked to DNA encoding a C to generate a recombinant wherein said wild-type produces rhamnosyltransferase A and rhamnosyltransferase B;'}{'i': P. chlororaphis', 'Pseudomonas, 'isolating recombinant that produces said rhamnosyltransferase C; and'}{'i': 'P. chlororaphis', 'culturing said isolated recombinant in medium capable of supporting rhamnose-lipid biosynthesis.'}72Pseudomonas. The method of wherein said rhamnosyltransferase C has the amino acid sequence of ...

METHODS OF GANGLIOSIDE PRODUCTION

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside wherein said ganglioside is selected from the group consisting of GM1, GM2, GM3, GD1a, GD1b, GD3 and GT1; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC 12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. (canceled)8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

HIGH-PURITY RUBUSOSIDE AND PROCESS FOR PRODUCING OF THE SAME

The invention provides a process of producing Rubusoside from steviol glycosides of plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. 1Stevia rebaudiana. A process for preparing Rubusoside from steviol glycosides of comprising the steps of:a. providing a solution comprising Stevioside;b. providing an enzyme composition comprising at least one enzyme selected from the group comprising rhamnosidase, β-glucosidase, β-glucanase, hesperidinase, naringinase, pectinase, cellulase, hemicellulase, xylanase;c. adding the enzyme composition to the solution comprising Stevioside to obtain reaction mixture;d. incubating the reaction mixture to facilitate complete or partial transformation of Stevioside to Rubusoside;e. recovering and purifying high purity Rubusoside from reaction mixture.2. A process of wherein step (a) the concentration of Stevioside is 1-50% (wt/vol) claim 1 , preferably 5-30% (wt/vol) claim 1 , more preferably 8-10% (wt/vol).3. A process of wherein step (d) the molar yield of Rubusoside from Stevioside is 1-100% claim 1 , preferably 80-100% and more preferably 95-100%.4. A process of wherein step (e) at least one purification techniques is employed selected from the group comprising ion exchange treatment claim 1 , macroporous adsorbent treatment claim 1 , membrane process claim 1 , chromatographic separation claim 1 , and crystallization from various solvent systems.5. A process of wherein step (e) the recovery and purification of Rubusoside comprises the steps of:a. providing reaction mixture containing Rubusoside;b. contacting the reaction mixture ...

SOPHOROLACTONE PRODUCTION

The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid, -continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the reaction mixture below 10 g/l, resulting in the crystallization of at least part of the sophorolactone present in the reaction mixture, -warming the reaction mixture to a temperature between 60° C. and 90° C., thereby melting the sophorolactone crystals, -allowing the molten sophorolactone to settle and to provide a crude sophorolactone composition, and -removing the crude sophorolactone composition from the remainder of the reaction mixture without use of an organic solvent. 1. Process for the selective production of sophorolactone in absence of an organic solvent , comprising the steps of:{'i': 'Candida', 'pre-cultivating cells of a species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained,'}cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid,continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the ...

CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS

The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I). 2. The method of claim 1 , wherein Ris optionally substituted aliphatic.3. The method of claim 1 , wherein Ris —(CH)—C(O)R.45-. (canceled)6. The method of claim 1 , wherein Ris optionally substituted aliphatic.7. The method of claim 6 , wherein Ris methyl or —CH═CH.89-. (canceled)10. The method of claim 6 , wherein Ris substituted with halo A —CN claim 6 , —NC claim 6 , —NCO claim 6 , —OCN claim 6 , —NCS claim 6 , —SCN claim 6 , —NO claim 6 , —N claim 6 , an amino group claim 6 , a hydroxyl group claim 6 , aryl claim 6 , heteroaryl claim 6 , or optionally substituted heterocyclyl.1121-. (canceled)22. The method of claim 1 , wherein Ris —CHaryl or —CHheteroaryl.2348-. (canceled)5051-. (canceled)52. The method of claim 1 , wherein the compound of formula (III) is GalNAz claim 1 , galactosamine claim 1 , GalNAc.5354-. (canceled)55. The method of claim 1 , wherein{'sup': '1', 'sub': '2', 'Ris —C(O)NH;'}{'sup': '2', 'Ris hydrogen;'}{'sup': '3', 'Ris —OH;'}W is —O—;{'sup': '4', 'Ris hydrogen;'}{'sup': '5', 'sub': '3', 'Ris —C(O)CH;'}{'sup': '6', 'Ris —OH;'}{'sup': '7', 'Ris —OH;'}{'sup': 'a', 'Ris hydrogen; and'}{'sup': 'b', 'Ris hydrogen.'}5758-. (canceled)59. The method of claim 1 , wherein Ris C(O)NHor —CHOH.60. (canceled)61. The method of claim 1 , wherein Ris hydrogen; and Ris —OH; or Ris hydrogen; and Ris —OH.62. (canceled)63. The method of claim 1 , wherein —W—Ris —OH claim 1 , —NHC(O)NH claim 1 , —OC(O)NHor —NHC(═NH)NH.6466-. (canceled)67. The method of claim 1 , wherein Ris —C(O)CH.68. (canceled)69. The method of claim 1 , wherein Ris —OH or —OR; wherein Ris a carbohydrate moiety.70. The method of claim 1 , wherein Ris —OH.7183-. (canceled)86. A kit comprising a compound of Formula (III) and a GalT enzyme.8792-. (canceled) The present ...

ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE

The present invention relates to an enzyme-catalyzed process for producing GDP- fucose from low-cost substrates guanosine and -fucose or guanosine and D-Mannose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Further, said process can be adapted to produce fucosylated molecules and biomolecules including glycans, such as human milk oligosaccharides, proteins, peptides, glycoproteins or glycopeptides. 2. The method according to claim 1 , wherein the solution comprises guanosine and -fucose; and{'smallcaps': L', 'L, 'the set of enzymes comprises a guanosine kinase, a polyphosphate kinase, and a -fucokinase/-fucose-1-phosphate guanylyltransferase.'}3. The method according to claim 1 , wherein the solution comprises guanosine and D-mannose; and{'smallcaps': L', 'L, 'the set of enzymes comprises a guanosine kinase, a polyphosphate kinase, and either (a) a glucokinase, phosphomannomutase, a mannose-1-phosphate guanylyltransferase, a GDP-mannose-4,6-dehydratase and a GDP--fucose- synthase or (b) an N-acetylhexosamine-1-kinase, a mannose-1-phosphate guanylyltransferase, a GDP-mannose 4,6-dehydratase and a GDP--fucose-synthase.'}4. The method according to claim 1 , wherein the set of enzymes further comprises a pyrophosphatase.5. The method according to claim 1 , wherein at least one enzyme of the set of enzymes is immobilized on a solid support.6. The method according to claim 1 , wherein the set of enzymes is co-immobilized on a solid support.7. The method according to claim 5 , wherein the at least one enzyme is immobilized on a solid support from cell lysate or the set of enzymes is co-immobilized on a solid support from cell lysate.8. The method according to claim 1 , wherein the concentration of guanosine and -fucose or guanosine and -mannose in the solution provided in A) is in the range of 0.2 mM to 5 claim 1 ,000 mM.9. The method according to claim 1 , wherein the polyphosphate is a long-chain polyphosphate having at ...

ONE STEP ENZYMATIC PROCESS FOR PRODUCING ALKYL FURANOSIDES

A process for enzymatically converting a furanoside substrate in a product of interest, includes contacting the substrate with an enzyme in presence of an alcohol acceptor, wherein the enzyme is preferably Araf51, and wherein the product is preferably an alkyl furanoside. The mutant Araf51 enzyme showing improved transglycosylation activity in comparison with the native wild-type (wt) Araf51 enzyme, and a method for screening the mutants are also described. 1. A process for enzymatically converting a furanosyl-containing polysaccharide substrate in a product of interest which is a furanoside , said process comprising contacting said substrate with an enzyme in presence of an alcohol acceptor.2. The process of being a one step process.3. The process of claim 1 , wherein the enzymatic conversion is a transglycosylation.4Clostridium thermocellumThermotoga maritimaThermobacillus xylaniliticusGeobacillus stearothermophilusAspergillus oryzaeBacillus subtilisCellvibrio japonicusStreptomyces avermitilisAspergillus kawachiiAspergillus terreus. The process of claim 1 , wherein the enzyme is selected from the group comprising proteins of the GH51 family claim 1 , such as claim 1 , for example claim 1 , Araf51 GH51 from (encoded by the nucleotide sequence SEQ ID NO: 1) claim 1 , Tm-AFase GH51 from (SEQ ID NO: 9) claim 1 , AbfD3 GH51 from (SEQ ID NO: 10) claim 1 , AbfAT-6 GH51 from (SEQ ID NO: 11) claim 1 , AbfA GH51 from (SEQ ID NO: 12); GH 43 from (SEQ ID NO: 13); Abf51A from (SEQ ID NO: 14); CBM42 GH42 from (SEQ ID NO: 15); AkabfB GH54 (SEQ ID NO: 16); and α-ara pI from (SEQ ID NO: 17).5Clostridium thermocellum. The process of claim 1 , wherein the enzyme is an Araf51 enzyme from (SEQ ID NO: 1).6. The process of claim 1 , wherein the enzyme is a native Araf51 enzyme.7. The process of claim 1 , wherein the enzyme is a mutant Araf51 enzyme claim 1 , wherein said mutant enzyme presents at least one of the following features:no inhibition in presence of alcohol acceptors; ...

PROCESS FOR PRODUCING A RHAMNOLIPID PRODUCED BY PSEUDOMONAS OR ENTEROBACTER USING ANDIROBA OR MURUMURU SEED WASTE

Process for producing a rhamnolipid produced by or using andiroba or murumuru seed waste, pertaining to the sector of compounds containing monosaccharide radicals, consists of producing rhamnolipids by a biotechnological process using andiroba or murumuru seed waste, following oil extraction, as a substrate for a or line cultivated in a bioreactor with a non-dispersive aeration system for reducing foam, producing a rhamnolipid content of 10.5 g/L for bacteria, in bioreactors carried out in a stirred tank with non-dispersive aeration using microporous membranes, particularly of silicone tubes, which allow oxygen to be supplied by diffusion. This type of aeration allows for various configurations, and in the embodiment of the invention, the porous membrane/tube was internally located in the liquid in the bioreactor in the form of a serpentine, under the following process conditions: pure oxygen with suitable pressure and flow rate to maintain O2 pressure in the bioreactor at 20% during the first 24 hours of the assay and stirring varying from 300 to 700 rpm, using 2 radial impellers and manual adjustment according to the decrease in the concentration of dissolved oxygen. The product produced has features that can be used primarily in the cosmetic industry due to its emulsifying, stability and non toxicity capacities. 17-. (canceled)8PseudomonasEnterobacter. A process for obtaining rhamnolipid from or using andiroba or murumuru seed residues , comprising the following steps:(a) reactivating the microorganism kept under refrigeration by means of growth in nutrient broth;(b) preparing the inoculum; and(c) batch bioprocessing in a stirred tank reactor under aeration conditions, [{'i': Pseudomonas', 'Enterobacter, 'step a) reactivates or microorganisms kept under cryopreservation refrigeration at a temperature ranging from −70 to −100° C., by growing in a nutrient broth for 10 to 30 hours, at a temperature of from 25 to 40° C., on a stirring platform at a stirring speed of ...

NOVEL COMPOUND DERIVED FROM PLANT OF GENUS QUAMOCLIT AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES

The present invention provides a novel compound isolated from a plant of the genus and a method for preparing a novel compound isolated from a plant of the genus through chemical synthesis, and relates to a novel compound and a composition containing the novel compound as an active ingredient for preventing or treating diabetes and diabetic complications. The compound derived from a plant of the genus and the composition containing the compound as an active ingredient according to the present invention have an excellent effect of promoting insulin secretion, thereby exhibiting efficacies in preventing or treating diabetes and the resulting various complications. 2. The compound of claim 1 , wherein Rand Rare each independently H or Calkyl.3. The compound of claim 1 , wherein both Rand Rare H.4Quamoclit.. The compound of claim 1 , wherein the compound is derived from a plant of the genus5QuamoclitQuamoclit angulata.. The compound of claim 4 , wherein the plant of the genus is9QuamoclitQuamoclit angulata.. The method of claim 6 , wherein the plant of the genus is10. The method of claim 8 , wherein the enzymatic treatment comprises the steps of:(i) treatment with at least one enzyme selected from the group consisting of cellulase, beta-glucanase, and xylanase; and(ii) treatment with at least one enzyme selected from the group consisting of glucosidase, cellulase, galactosidase, amyloglucosidase, xylosidase, and xylanase.12. The method of claim 11 , wherein both Rand Rare H.13. The method of claim 11 , wherein the sugar in step (b) comprises at least one selected from the group consisting of glucose claim 11 , fucose claim 11 , rhamnose claim 11 , arabinose claim 11 , xylose claim 11 , quinovose claim 11 , maltose claim 11 , glucuronic acid claim 11 , ribose claim 11 , N-acetyl glucosamine claim 11 , and galactose.14. The method of claim 11 , wherein the reaction solvent comprises at least one selected from the group consisting of aliphatic or aromatic hydrocarbons ...

Method for Producing Oligosaccharides and Oligosaccharide Glycosides by Fermentation

The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor. The application further discloses a method for producing an oligosaccharide comprising the steps of: (a) culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor to produce an anomerically protected glycosidic oligosaccharide derivative, then (b) removing/deprotecting the anomeric protective group. 1. A method for producing an oligosaccharide derivative having an aglycon R , wherein R is OR , which Ris a group removable by catalytic hydrogenolysis , or R is —SR , which Ris selected from optionally substituted alkyl , optionally substituted aryl and optionally substituted benzyl , or R is azide , or R is —NH—C(R″)═C(R′) , wherein each R′ independently of each other is an electron withdrawing group selected from —CN , —COOH , —COO-alkyl , —CO-alkyl , —CONH , —CONH-alkyl and —CON(alkyl) , or wherein the two R′-groups are linked together and represent —CO—(CH)—CO— and thus form with the carbon atom to which they are attached a 5-7 membered cycloalkan-1 ,3-dion , in which dion any of the methylene groups is optionally substituted with 1 or 2 alkyl groups , and R″ is H or alkyl , said method comprising the step of culturing , in a culture medium containing a lactose acceptor having the aglycon R , wherein R is as defined above , a genetically modified cell having a recombinant gene that encodes an enzyme capable of modifying said lactose acceptor or one of the ...

GLYCOSYLATED AROMA- AND FRAGRANCE PRECURSORS AND FRAGRANCE PRODUCTS THAT CAN BE ACTIVATED

The present invention discloses biotechnologically produced inactive aroma- and fragrance/scent precursors in new concentration ranges beyond those of natural aroma glycoside sources, which can be activated by external triggers like enzymes, temperature and p H, and then release the aroma and the fragrance. 1. Product or composition comprising at least one aroma glycoside comprising an aglycone component and at least one sugar component , wherein the concentration of the at least one aroma glycoside is higher than its concentration in natural products or compositions.2. Product or composition according to claim 1 , wherein the aroma is at least one selected from the list of compounds consisting of eugenol claim 1 , citronellol claim 1 , thymol claim 1 , carvacrol claim 1 , furaneol claim 1 , 1-hexanol claim 1 , homofuraneol claim 1 , norfuraneol claim 1 , menthol claim 1 , raspberry ketone claim 1 , maltol claim 1 , ethylmaltol claim 1 , 2-furfurylthiol claim 1 , 2-methyl-3-furanthiol claim 1 , 3-mercapto-2-pentanon claim 1 , 1-octen-3-ol claim 1 , sotolon claim 1 , 4-mercapto-4-methylpentan-2-on claim 1 , (3-methylthio)-1-propanol claim 1 , and phenylethanol claim 1 , preferably from thymol claim 1 , carvacrol claim 1 , furaneol claim 1 , homofuraneol claim 1 , norfuraneol claim 1 , raspberry ketone claim 1 , maltol claim 1 , ethylmaltol claim 1 , 2-furfurylthiol claim 1 , 2-methyl-3-furanthiol claim 1 , 3-mercapto-2-pentanon claim 1 , sotolon claim 1 , 4-mercapto-4-methylpentan-2-on claim 1 , and (3-methylthio)-1-propanol claim 1 , more preferably from carvacrol claim 1 , norfuraneol claim 1 , raspberry ketone claim 1 , 2-furfurylthiol claim 1 , 2-methyl-3-furanthiol claim 1 , 3-mercapto-2-pentanon claim 1 , sotolon claim 1 , 4-mercapto-4-methylpentan-2-on claim 1 , and (3-methylthio)-1-propanol.3. Product or composition according to claim 1 , wherein the concentration of the at least one aroma glycoside is 1-10000 ppm claim 1 , preferably 10-1000 ppm claim 1 , ...

MONOESTER SUGAR DERIVATIVES AS FLAVOR MODIFIERS

Compositions containing monoester derivatives of the primary alcohol residue of a sugar are generally disclosed herein, as well as their use as sweetness enhancers, bitterness maskers, sourness maskers, or astringency reducers, to improve the taste profile of a flavored article. 1. A flavored article comprising a flavor-enhancing compound , wherein the flavor-enhancing compound is a monoester derivative of a primary alcohol residue of a sugar compound , which comprises a sugar moiety and an acid moiety.2. The flavored article of claim 1 , wherein the sugar moiety of the flavor-enhancing compound is a monosaccharide moiety.3. The flavored article of claim 2 , wherein the sugar moiety of the flavor-enhancing compound is a hexose moiety.4. The flavored article of claim 3 , wherein the sugar moiety of the flavor-enhancing compound is an allose moiety claim 3 , an altrose moiety claim 3 , a glucose moiety claim 3 , a mannose moiety claim 3 , a gulose moiety claim 3 , an idose moiety claim 3 , a galactose moiety claim 3 , a talose moiety claim 3 , a psicose moiety claim 3 , a fructose moiety claim 3 , a sorbose moiety claim 3 , or a tagatose moiety.5. The flavored article of claim 4 , wherein the sugar moiety of the flavor-enhancing compound is a glucose moiety.6. The flavored article of any one of to claim 4 , wherein the acid moiety of the flavor-enhancing compound is a Cfatty acid moiety.7. The flavored article of claim 6 , wherein the acid moiety of the flavor-enhancing compound is a hexanoate moiety claim 6 , an octanoate moiety claim 6 , a decanoate moiety claim 6 , a 9-decenoate moiety claim 6 , a 10-undecenoate moiety claim 6 , a dodecanoate moiety claim 6 , a 9-dodecenoate moiety claim 6 , a tetradecanoate moiety claim 6 , a hexadecanoate moiety claim 6 , an octadecanoate moiety claim 6 , an oleate moiety claim 6 , a linoleate moiety claim 6 , a linolenate moiety claim 6 , an eicosapentaenoate moiet claim 6 , or a docosahexaenoate moiety.8. The flavored article ...

GLYCOLIPOPEPTIDE BIOSURFACTANTS

Surfactants based on a newly discovered class of compounds include a hydrophobic lipid oligomer covalently linked to a peptide or peptide-like chain and a carbohydrate moiety, and a serine-leucinol dipeptide linked to the lipid oligomer. Such surfactants can be used to create an oil-in-water or water-in-oil emulsion by mixing together a polar component; a non-polar component; and the surfactant. Biosurfactants of the newly discovered class can be made by isolating and culturing a microorganism which produces the biosurfactant, and then isolating the biosurfactant from the culture. A microorganism can be engineered to produce biosurfactant of this newly discovered class by expressing a set of heterologous genes involved in the biosynthesis of the biosurfactant in the microorganism. 1. A purified biosurfactant comprising a hydrophobic lipid component comprising a carboxyl end and a hydroxyl end , wherein the lipid component is covalently linked to (i) a peptide or peptide-like chain at the carboxyl end of the lipid component and (ii) a carbohydrate moiety at the hydroxyl end of the lipid component via a glycosidic linkage.2. The purified biosurfactant according to claim 1 , wherein the peptide chain comprises in the range of between 2 and 10 amino acids.3. The purified biosurfactant according to claim 1 , wherein the lipid component comprises in the range of between 1 and 6 alkanoic acid moieties4. The purified biosurfactant according to claim 1 , wherein the lipid component comprises an acyle chain claim 1 , and wherein the length of each said acyl chain is in the range of between Cto C.5. The purified biosurfactant according to claim 1 , wherein the carbohydrate moiety may be selected from saccharides including glucose claim 1 , fructose claim 1 , galactose claim 1 , mannose claim 1 , ribose claim 1 , or deoxy saccharide variants including deoxyribose claim 1 , fucose claim 1 , or rhamnose.6. The purified biosurfactant according to claim 1 , wherein the peptide or ...

Production of monoacyl mel

Provided is a means for efficiently producing a monoacyl MEL. This means comprises culturing a monoacyl-MEL-producing microorganism in the presence of a surfactant.

Novel cell wall polymers of enterococcus faecalis and uses thereof

The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.

MONOTERPENE GLYCOSYLTRANSFERASE ORIGINATING FROM HOP AND METHOD FOR USING SAME

The object of the present invention is to provide -derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. 1. A protein of any one selected from the group consisting of (a) to (c) shown below:(a) a protein which consists of the amino acid sequence shown in SEQ ID NO: 2, 4 or 6;(b) a protein which consists of an amino acid sequence with deletion, substitution, insertion and/or addition of 1 to 95 amino acids in the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound; and(c) a protein which has an amino acid sequence sharing a sequence identity of 80% or more with the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound.2. The protein according to claim 1 , wherein the monoterpene compound is geraniol or linalool.3. A polynucleotide of any one selected from the group consisting of (a) to (e) shown below:(a) a polynucleotide containing the nucleotide sequence shown in SEQ ID NO: 1, 3 or 5;(b) a polynucleotide encoding a protein which consists of the amino acid sequence shown in SEQ ID NO: 2, 4 or 6;(c) a polynucleotide encoding a protein which consists of an amino acid sequence with deletion, substitution, insertion and/or addition of 1 to 95 amino acids in the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound;(d) a polynucleotide encoding a protein which has an amino acid sequence sharing a sequence identity of 80% or more with the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound; and(e) a polynucleotide which is hybridizable under high stringent conditions with a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3 or 5 and which encodes a protein having glycosylation activity on a monoterpene compound ...

Recombinant Production of Steviol Glycosides

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express recombinant genes encoding UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol glycosides, e.g., Rebaudioside A and/or Rebaudioside D, which can be used as natural sweeteners in food products and dietary supplements. 1. A method for producing a target steviol glycoside or a target steviol glycoside composition , comprising contacting a starting composition comprising a steviol , a precursor steviol glycoside having a 13-O-glucose , a 19-O-glucose , or both a 13-O-glucose and a 19-O-glucose , and/or a mixture thereof with a first uridine 5′-diphospho (UDP) glycosyl transferase polypeptide capable of beta 1 ,2 glycosylation of a C2′ of the 13-O-glucose , the 19-O-glucose , or both the 13-O-glucose and the 19-O-glucose of the precursor steviol glycoside and one or more UDP-sugars , under suitable reaction conditions to transfer one or more sugar moieties from the one or more UDP-sugars to the steviol , the precursor steviol glycoside , and/or the mixture thereof , thereby producing the target steviol glycoside or the target steviol glycoside composition;wherein the first 5′-UDP glycosyl transferase polypeptide is capable of converting Rebaudioside A (RebA) to Rebaudioside D (RebD) at a rate that is at least 20 times faster than the rate at which a UDP glycosyl transferase polypeptide having the amino acid sequence set forth in SEQ ID NO:5 is capable of converting RebA to RebD under corresponding reaction conditions; and/orwherein the first 5′-UDP glycosyl transferase polypeptide is capable of converting higher amounts of RebA to RebD compared to the UDP glycosyl transferase polypeptide having the amino acid sequence set forth in SEQ ID NO:5 under corresponding reaction conditions.2. A method of transferring a second sugar moiety to a C2′ of the 13-O-glucose , the 19-O-glucose , or both the 13-O-glucose and the 19-O-glucose ...

BIOSURFACTANT-PRODUCING RECOMBINANT MICROORGANISM

Provided is a means for increasing mannosylerythritol lipid (MEL) production efficiency. The present invention is a mannosylerythritol-lipid-producing microorganism transformed with an expression vector having a gene that encodes a lipase under the control of E5Pgap promoter or E5Ptef promoter. 1. A mannosylerythritol-lipid-producing microorganism transformed with an expression vector containing a gene that encodes a lipase under the control of E5Pgap promoter or E5Ptef promoter.2Pseudozyma.. The mannosylerythritol-lipid-producing microorganism according to claim 1 , wherein the mannosylerythritol-lipid-producing microorganism is a microorganism of the genus3Pseudozyma.. The mannosylerythritol-lipid-producing microorganism according to claim 1 , wherein the gene that encodes a lipase is derived from a microorganism of the genus4Pseudozyma tsukubaensis.. The mannosylerythritol-lipid-producing microorganism according to claim 1 , wherein the mannosylerythritol-lipid-producing microorganism is5. An expression vector containing a gene that encodes a lipase under the control of E5Pgap promoter or E5Ptef promoter.6Pseudozyma.. The expression vector according to claim 5 , wherein the gene that encodes a lipase is derived from a microorganism of the genus7. The expression vector according to claim 5 , which is an expression vector for transforming a mannosylerythritol-lipid-producing microorganism.8. A method for producing a transformed mannosylerythritol-lipid-producing microorganism claim 5 , the method comprising transforming a mannosylerythritol-lipid-producing microorganism with the expression vector of .9. A method for producing a mannosylerythritol lipid using the mannosylerythritol-lipid-producing microorganism of .10. A method for producing a mannosylerythritol lipid claim 1 , the method comprising culturing the mannosylerythritol-lipid-producing microorganism of in a medium containing a vegetable oil. A technique for producing a biosurfactant by using a ...

IVERMECTIN B1B PRODUCING STRAIN AND USE THEREOF

Provided are a strain C63-51 with a high yield of ivermectin B1b and a method for producing ivermectin B1b by using this strain. By using the above-mentioned strain and method, efficient production of single ivermectin B1b can be achieved. 1Streptomyces avermitilis. A strain C63-51 , deposited on Dec. 22 , 2016 in the China General Microbiological Culture Collection Center (CGMCC) with an accession number CGMCC NO. 13370.2Streptomyces avermitilis. A composition comprising the strain C63-51 according to .3Streptomyces avermitilis. A method of manufacturing ivermectin B1b or a pharmaceutical composition containing ivermectin B1b comprising using the strain C63-51 according to .4Streptomyces avermitilis. A method of producing ivermectin B1b comprising performing fermentation in a medium containing an assimilable carbon source and/or nitrogen source using the strain C63-51 according to .5. The method according to claim 4 , wherein the assimilable carbon source is one or more of sucrose claim 4 , glucose claim 4 , amylase claim 4 , fructose claim 4 , rhamnose claim 4 , raffinose claim 4 , xylose claim 4 , arabinose claim 4 , industrial molasses claim 4 , lactose claim 4 , galactose claim 4 , maltose claim 4 , trehalose claim 4 , xylan claim 4 , dextrin claim 4 , corn starch claim 4 , sorbitol claim 4 , salicin claim 4 , inositol claim 4 , mannitol claim 4 , glycerol claim 4 , glycine or inulin.6. The method according to claim 4 , wherein the assimilable nitrogen source is one or more of beef extractum claim 4 , yeast extractum claim 4 , yeast extract claim 4 , yeast powder claim 4 , peptone claim 4 , tryptone claim 4 , gluten powder claim 4 , cottonseed meal claim 4 , peanut meal claim 4 , soybean meal claim 4 , dried powder of corn steep liquor claim 4 , bran claim 4 , urea claim 4 , ammonium salt or nitrate.7. The method according to ; wherein the medium further comprises an inorganic salt claim 4 , and the inorganic salt is one or more of MnSO claim 4 , NaMoO claim 4 ...

Biosynthesis of Phenylpropanoid and Dihydrophenylpropanoid Derivatives

Provided herein are methods and compositions for producing phenylpropanoid derivatives, such as chalcones and stilbenes, and dihydrophenylpropanoid derivatives, such as dihydrochalcones and dihydrostilbenes, in microorganisms. In particular, the disclosure provides recombinant microorganisms and methods of use thereof for producing phenylpropanoid derivative compounds and dihydrophenylpropanoid derivative compounds.

MUTANT SUCROSE PHOSPHORYLASES WITH IMPROVED GLYCOSYLATION ACTIVITY TOWARDS POLYPHENOLS

The present invention relates to glycosylating polyphenols via biocatalysis. More specifically the present invention discloses particular mutants of the thermostable sucrose phosphorylase derived from the microorganism which efficiently glycosylate polyphenols such as resveratrol. 1. An in vitro method to glycosylate a polyphenol comprising:contacting in vitro a sucrose phosphorylase comprising the amino acid sequence of SEQ ID N° 1, SEQ ID N° 2, SEQ ID N° 3, SEQ ID N° 4 or SEQ ID N° 5 with sucrose or alpha-glucose-1-phosphate, and, a polyphenol, andglycosylating said polyphenol.2. The in vitro method according to wherein said polyphenol is a stilbenoid.3. The in vitro method according to wherein said stilbenoid is resveratrol.4. The in vitro method according to wherein said polyphenol is a flavonoid.5. The in vitro method according to wherein said flavonoid is apigenine claim 4 , hesperetin claim 4 , quercetin or epicatechin6. The in vitro method according to wherein said polyphenol is a phenoxyphenol.7. An in vitro method to glycosylate a polyphenol comprising:contacting in vitro a sucrose phoshorylase with sucrose or alpha-glucose-1 phosphate, and, a polyphenol, and,glycosylating said polyphenol, wherein said sucrose phoshorylase is a fragment of SEQ ID N° 1, 2, 3, 4 or 5 that has at least 90% sequence identity with SEQ ID N° 1, 2, 3, 4 or 5 and wherein said fragment comprises, in addition to having the amino acid A,V,T or G at position 134 of SEQ ID N° 1-4, respectively, or having a deletion at position 134 as shown by SEQ ID N° 5, at least the following 16 catalytic amino acids of SEQ ID N° 6: D49, F52, H87, F157, Q165, R195, D197, A198, Y201, E238, H240, H295, D296, D342, Q345 and R399.8Thermoanaerobacterium thermosaccharolyticum. A variant of the thermostable sucrose phosphorylase derived from the microorganism comprising SEQ ID N° 2 claim 7 , 3 claim 7 , 4 or 5 claim 7 , or claim 7 , comprising a fragment according to . The present invention relates to ...

TRANS-RESVERATROL POLYSACCHARIDE, METHOD FOR PRODUCING THE SAME, AND COMPOSITION COMPRISING THE SAME

An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. Another object of the present invention is to provide a trans-resveratrol derivative that has no toxicity against cells and has sufficient antioxidative properties and/or a sufficient whitening effect. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin glucanotransferase. 1. At least one trans-resveratrol polysaccharide selected from the group consisting of:trans-resveratrol-3-O-β-D-diglucoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position of trans-resveratrol-3-O-β-D-diglucoside via glycoside linkage;trans-resveratrol-4′-O-β-D-diglucoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position of trans-resveratrol-4′-O-β-D-diglucoside via glycoside linkage;trans-resveratrol-O-β-D-3-diglucoside-4′-monoglycoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position of trans-resveratrol-O-β-D-3-diglucoside-4′-monoglycoside via glycoside linkage;trans-resveratrol-O-β-D-3-monoglucoside-4′-diglycoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G′-4 position of trans-resveratrol-O-β-D-3-monoglucoside-4′-diglycoside via glycoside linkage; andtrans-resveratrol-O-β-D-3-diglucoside-4′-diglycoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position and/or the 2G′-4 position of trans-resveratrol-O-β-D-3-diglucoside-4′-diglycoside via glycoside linkage.2. The trans-resveratrol polysaccharide according to claim 1 , wherein the sugar is at least one monosaccharide selected from the group consisting of glucose claim 1 , galactose claim 1 , mannose claim 1 , xylose claim 1 , fructose claim 1 , rhamnose ...

Method for utilizing extraction residue of yeast extract

To produce a glucosylceramide composition suitable for a functional food or a medicinal product, having stable quality, and cleared of contaminants such as sterol glycosides. An objective is to produce a glucosylceramide composition at low cost from a raw material which is safe, has been eaten by human beings, and is readily available. A glucosylceramide-containing composition is produced by extraction from a raw material of a yeast residue in an organic solvent, such as an alcohol, the yeast residue being obtained after extraction of yeast extract from Torula yeast or the like.

GENETICALLY MODIFIED HOST CELLS PRODUCING GLYCOSYLATED CANNABINOIDS

The present invention relates to a microbial host cell genetically modified to intracellularly produce a cannabinoid glycoside, said cell expressing a heterologous gene encoding a glycosyl transferase which has a at least 70% identity to the glycosyl transferase comprised in SEQ ID NO: 157 or 207, capable of intracellularly glycosylating a cannabinoid acceptor with a glycosyl donor thereby producing the cannabinoid glycoside. 1. A microbial host cell genetically modified to intracellularly produce a cannabinoid glycoside , said cell expressing a heterologous gene encoding a glycosyl transferase which has at least 70% identity to the glycosyl transferase of SEQ ID No: 157 or 207 , wherein the glycosyl transferase is capable of intracellularly glycosylating a cannabinoid acceptor with a glycosyl donor thereby producing the cannabinoid glycoside.2. The microbial host cell of claim 1 , wherein the cannabinoid acceptor is a cannabinoid aglycone or a cannabinoid glycoside selected from the group of cannabichromene-type (CBC) claim 1 , cannabigerol-type (CBG) claim 1 , cannabidiol-type (CBD) claim 1 , Tetrahydrocannabinol-type (THC) claim 1 , cannabicyclol-type (CBL) claim 1 , cannabielsoin-type (CBE) claim 1 , cannabinol-type (CBN) claim 1 , cannabinodiol-type (CBND) and cannabitriol-type (CBT).3. The microbial host cell of claim 1 , wherein the cannabinoid acceptor is selected from the group of cannabigerolic acid (CBGA) claim 1 , cannabigerolic acid monomethylether (CBGAM) claim 1 , cannabigerol monomethylether (CBGM) claim 1 , cannabigerovarinic acid (CBGVA) claim 1 , cannabigerovarin (CBGV) claim 1 , cannabichromenic acid (CBCA) claim 1 , cannabichromevarinic acid (CBCVA) claim 1 , cannabichromevarin (CBCV) claim 1 , cannabidiolic acid (CBDA) claim 1 , cannabidiol claim 1 , monomethylether (CBDM) claim 1 , cannabidiol-C4 (CBD-C4) claim 1 , cannabidivarinic acid (CBDVA) claim 1 , cannabidivarin (CBDV) claim 1 , cannabidiorcol (CBD-C1) claim 1 , Δ9-trans- ...

MICROBIAL PRODUCTION OF TERPENOIDS

The present invention provides genetically engineered host organisms capable of producing terpenoids. The present invention also relates terpenoids obtained from such genetically engineered organisms. Examples of the produced terpenoids include carotenoids, ionones, abienol, and other isoprenoid derived compounds. In addition, the invention relates to a methods of for the preparation of terpenoids using such a genetically engineered organism. 121-. (canceled)22. A genetically modified microorganism comprising a polynucleotide molecule encoding a geranylgeranyl pyrophosphate (GGPP) synthase that produces at least one terpenoid derived from GGPP , wherein said polynucleotide molecule is selected from the group consisting of:(a) a nucleic acid molecule comprising a polynucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:2;(b) a nucleic acid molecule comprising a polynucleotide sequence encoding a protein having an amino acid sequence with substitution, deletion, insertion and/or addition of one or several amino acid residues in the amino acid sequence of SEQ ID NO:2, the protein having GGPP synthase activity; and(c) a nucleic acid molecule comprising a polynucleotide sequence encoding a protein having at least 90% identity to the amino acid sequence of SEQ ID NO:2, the protein having GGPP synthase activity;and further comprising at least one recombinant nucleotide sequence encoding at least one polypeptide selected from the group consisting of:(a) a polypeptide having phytoene synthase activity,(b) a polypeptide having phytoene dehydrogenase activity,(c) a polypeptide having lycopene beta-cyclase activity;(d) a polypeptide having lycopene epsilon-cyclase activity; and(e) a polypeptide having carotenoid cleavage dioxygenase activity.23. The genetically modified microorganism of claim 22 , wherein said microorganism has an increased GGPP synthase activity compared with the same microorganism without said polynucleotide molecule.24. The ...

Recombinant bacillus subtilis for synthesizing lacto-N-neotetraose and application thereof

The disclosure discloses recombinant for synthesizing e lacto-N-neotetraose yield. The recombinant is obtained by integrating two β-1,4-galactotransferase genes on a genome of a host bacterium 168ΔamyE:P-lacY, P-lgtB, P-comK and exogenously expressing a β-1,3-N-glucosaminotransferase gene. Compared with a strain before transformation, the recombinant of the disclosure improves the yield of the synthesized lacto-N-neotetraose from 720 mg/L to 1300 mg/L, laying a foundation for further metabolic engineering transformation of for producing the lacto-N-neotetraose. 1Bacillus subtilisBacillus subtilisBacillus subtilis. Recombinant for synthesizing lacto-N-neotetraose , wherein the recombinant is obtained by the following steps: integrating two β-1 ,4-galactotransferase genes on a genome of a host bacterium 168ΔamyE:P-lacY , P-lgtB , P-comK; and exogenously expressing a β-1 ,3-N-glucose aminotransferase gene.2Bacillus subtilisBacillus subtilis. The recombinant of claim 1 , wherein the host bacterium is obtained by the following steps: using 168 as a starting strain claim 1 , regulating the expression of a gene comK by a promoter P claim 1 , integrating a lactose permease-encoding gene onto an amyE site of the genome claim 1 , and integrating a β-1 claim 1 ,4-galactotransferase-encoding gene between a ydeS site and a ydzO site of the genome.3Bacillus subtilis. A method for constructing the recombinant of claim 1 , comprising the following steps:{'sub': '43', '(1) constructing a recombinant fragment containing homologous arms of ydaH and ydzA genes, a β-1,4-galactotransferase gene, a Ppromoter, and a bleomycin resistance gene sequence by fusion PCR;'}{'sub': '43', '(2) constructing a recombinant fragment containing homologous arms of yszA and ysxE genes, a β-1,4-galactotransferase gene, a Ppromoter, and a chloramphenicol resistance gene sequence by fusion PCR;'}{'i': Bacillus subtilis', 'Bacillus subtilis, 'sub': 43', '43, '(3) transforming the recombinant fragment ...

Matrix Fermentation Systems and Methods for Producing Microbe-Based Products

The subject invention provides methods of producing advantageous microbes and/or by-products using a modified form of solid-state fermentation, or matrix fermentation. In particular, the methods utilize foodstuff mixed with liquid nutrient medium to produce a three-dimensional scaffold substrate having ample surface area on which the microbes can grow. The methods can be used to cultivate yeasts, fungi and bacteria at high concentrations without susceptibility to total contamination. The subject invention can be used in remote locations and can be transported with ease.

MEANS AND METHODS FOR RHAMNOLIPID PRODUCTION

Provided is a host cell comprising a rhlA gene or an ortholog thereof, under the control of a heterologous promoter and a rhlB gene or an ortholog thereof, under the control of a heterologous promoter. The host cell is capable of achieving a carbon yield of more than 0.18 Cmol rhamnolipid/Cmol substrate. Provided is also a method of producing rhamnolipids, employing such a host cell. 1. A host cell comprising(a) a rhlA gene or an ortholog thereof, being under the control of a heterologous promoter; and(b) a rhlB gene or an ortholog thereof, being under the control of a heterologous promoter,wherein said host cell is capable of achieving a carbon yield of more than 0.18 Cmol rhamnolipid/Cmol substrate.2. The host cell of claim 1 , wherein the bacterial host cell further comprises a rhlC gene or an ortholog thereof claim 1 , being under the control of a heterologous promoter.3. The host cell of claim 1 , being a prokaryotic host cell or a yeast host cell.4. The host cell of claim 1 , wherein the prokaryotic host cell is a bacterial host cell.5. The host cell of claim 1 , wherein the host cell is incapable of producing poly(3-hydroxyalkanoates) (PHA).6. The host cell of claim 5 , having a knock-out mutation in an endogenous sequence encoding poly(3-hydroxyalkanoic acid) synthase 1.7. The host cell of claim 1 , wherein the host cell is of a phylum selected from Proteobacteria claim 1 , Planctomycetes claim 1 , Actinobacteria and Firmicutes.8. The host cell of claim 1 , the cell being gram-negative.9. The host cell of claim 1 , wherein the host cell is non-pathogenic for a human subject.10PseudomonasAcidobacterium. The host cell of claim 7 , wherein the host cell is (i) a sp. claim 7 , proteobacterium of one of the classes Alphaproteobacteria claim 7 , Betaproteobacteria claim 7 , Gammaproteobacteria and Deltaproteobacteria or (ii) an of one of the classes Acidobacteriales and Solibacteres.11AcinetobacterEnterobacterPantoeaPseudomonas sp, ...

Processing biomass

Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.

METHODS TO PRODUCE BOLAAMPHIPHILIC GLYCOLIPIDS

This disclosure relates to the field of the microbial production of specific types of glycolipids that are potentially useful as replacements for petroleum-based detergents and emulsifiers. This disclosure, more specifically, discloses the usage of yeasts having a dysfunctional acetyltransferase for producing high amounts of bolaamphiphilic glycolipids when using conventional and cheap substrates. Furthermore, the disclosure relates to yeasts having a dysfunctional acetyltransferase optionally combined with a dysfunctional lactonase and/or second glucosyltransferase. The latter microorganisms are capable of producing high amounts of bolaamphiphilic sophorolipids. 115.-. (canceled)16. A method of producing bolaamphiphilic glycolipids having a hydrophobic spacer with hydrophilic glucose molecules at both ends of the spacer , the method comprising:utilizing a fungal strain that comprises a dysfunctional acetyltransferase,{'i': Starmerella', 'Candida', 'bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellate, Candida kuoi, Candida', 'Rhodotorula bogoriensis', 'Wickerhamiella domericqiae', 'Starmerella, 'wherein the fungal strain is selected from the group consisting of () sp. NRRL Y-27208, sp., and a sophorolipid-producing strain of the clade.'}17. The method according to claim 16 , wherein the fungal strain further comprises a dysfunctional lactonase.18. The method according to claim 16 , wherein the fungal strain further comprises a dysfunctional second glucosyltransferase.19. A method of producing bolaamphiphilic glycolipids having a hydrophobic spacer with hydrophilic glucose molecules at both ends of the spacer claim 16 , the method comprising:{'i': Starmerella', 'Candida', 'bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellate, Candida kuoi, Candida', 'Rhodotorula bogoriensis', 'Wickerhamiella domericqiae', 'Starmerella, 'culturing a fungal strain comprising a ...

LONG CHAIN GLYCOLIPIDS USEFUL TO AVOID PERISHING OR MICROBIAL CONTAMINATION OF MATERIALS

The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. 2. Method according to claim 1 , where the material to which the compound is added is a cosmetic claim 1 , a food or a beverage.5. Method according to claim 1 , where at least one additional preservative is added.6. Method according to claim 1 , where the compound or compounds of the formula I claim 1 , a physiologically acceptable salt thereof claim 1 , and/or an ester thereof claim 1 , is added in the form of an extract from a natural source or obtained from such an extract.7Dacryopinax spathularia, Ditiola radicata, Ditiola nudaFemsjonia luteoalbaDitiola pezizaeformis. Method according to claim 6 , where the source of the extract is strain FU50088strain MUCL 53180strain CBS 173.60 or -(=) strain MUCL 53500.10. The composition according to claim 8 , which is a precursor of a beverage.13. The material according to claim 12 , where the beverage is selected from the group consisting of water claim 12 , flavoured water claim 12 , fortified water claim 12 , a flavoured beverage claim 12 , carbonated water claim 12 , a juice claim 12 , cola claim 12 , lemon-lime claim 12 , ginger ale claim 12 , root beer beverages which are carbonated in the manner of soft drinks claim 12 , a syrup claim 12 , a diet beverages claim 12 , a carbonated soft drink claim 12 , a fruit juice claim 12 , other fruit containing beverages which provide the flavor of fruit juices and contain greater than 0% fruit juice but less than 100% fruit juice claim 12 , fruit flavored beverages claim 12 , vegetable juices claim 12 , vegetable containing beverages claim 12 , which provide the flavor of any of the aforementioned vegetable juices and contain greater than 0% vegetable juice but less than 100% vegetable juice claim 12 , isotonic beverages claim 12 , ...

METHODS FOR ENABLING FARNESENE ACCUMULATION IN PLANTS AND RELATED COMPOSITIONS

The invention provides novel methods and compositions directed to farnesol production, accumulation and cellular sequestration in plants. More specifically, the methods of the invention comprise modifying plant cells that express farnesene to convert the farnesene to farnesol, and in some cases, to farnesol glycoside, such as farnesol glucoside. In other embodiments, carbon flux is shunted towards sesquiterpene production by applying certain plant growth regulators and herbicides to increase sesquiterpene production. 1. A method of accumulating at least one sesquiterpene in a plant cell comprisinga) expressing a transgene encoding an exogenous polypeptide that hydroxylates at least one sesquiterpene in the plant cell, andb) accumulating the hydroxylated sesquiterpene within the plant cell, wherein the hydroxylated sesquiterpene is less volatile than at least one unhydroxylated sesquiterpene and thereby accumulates within the plant cell.2. The method of claim 1 , wherein the plant cell produces a greater amount of the at least one sesquiterpene when compared to that produced by a non-transgenic cell of the same genotype that does not express the transgene.3. The method of claim 1 , wherein the plant cell is a transgenic plant cell engineered to produce elevated amounts of the at least one sesquiterpene when compared to the amount of at least one sesquiterpene produced by a non-transgenic cell of the same genotype in the absence of expression of the exogenous polypeptide.4. The method of claim 2 , wherein the at least one sesquiterpene is farnesene.5. The method of claim 4 , wherein the hydroxylated sesquiterpene is farnesol.6. The method of claim 5 , wherein the exogenous polypeptide is a farnesol synthase or a cytochrome P450 enzyme.7. The method of claim 6 , wherein the exogenous polypeptide comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO:2 or SEQ ID NO:10 claim 6 , or an active fragment thereof.8. (canceled)9. The method of ...

METHOD FOR PRODUCING A MINOR GINSENOSIDE USING A GINSENOSIDE GLYCOSIDASE

Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from a sp. () microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside. 1. A method of producing a minor ginsenoside which is deglycosylated at the C-6 position , comprising:treating one or more selected from the group consisting of a ginsenoside glycosidase protein having an amino acid sequence of SEQ ID NO: 1; a transformant introduced with a vector comprising a polynucleotide encoding the protein; and a culture of the transformant to a ginsenoside having a sugar at the C-6 position.2. The method of claim 1 , wherein the ginsenoside having a sugar at the C-6 position is one or more selected from the group consisting of Rg claim 1 , Rh claim 1 , Re claim 1 , Rgand Rf.3. The method of claim 1 , wherein the sugar is glucose claim 1 , Glc(1→2)Glc claim 1 , or rha(1→2)Glc.4. The method of claim 1 , wherein the method comprises one or more selected from the group consisting of conversion of Rginto F claim 1 , conversion of Rhinto protopanaxatriol (PPT) claim 1 , conversion of Re into F claim 1 , conversion of Rginto PPT claim 1 , and conversion of Rf into F.5. The method of claim 1 , wherein the deglycosylation is performed at pH 5 to pH 8.5 or at a temperature of 10° C. to 50° C. This application claims priority under 35 U.S.C. §119 to Korean Patent Application No. 10-2015-0181763, filed Dec. 18, 2015, the disclosure of which is incorporated herein by reference.1. Field of the InventionThe present invention relates to a method of producing a minor ginsenoside using a ginsenoside glycosidase protein derived from a sp. microorganism, and a composition including the ...

Bioactive Alkaloid Compositions and Their Medical Uses

The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from preferably selected among and ; methods of manufacturing such bioactive alkaloid fractions and their use for the inhibition of IKK-β, PDE4 and/or PDE5 and in addition their promoting effect on mitochondrial biogenesis and function; their therapeutic or non-therapeutic applications as nutritive or medicinal products in the management of conditions associated with impaired mitochondrial function or IKK-β, PDE4 and/or PDE5 activity, such as inflammation, neurodegeneration, dyslipidemia, type 2 diabetes mellitus, impaired wound healing, sarcopenia and other conditions associated with muscle dysfunction or tiredness and fatigue, or where optimization of muscular or cognitive function is desired; extracts, juices or concentrates of comprising such alkaloids; compositions comprising such alkaloids, including pharmaceutical compositions, nutritive product such as functional foods and nutraceutical compositions, and cosmetic compositions and medical devices. 2. The alkaloid compound according to claim 1 , wherein the compound is (E)-(E)-2-cyano-4-(((2R claim 1 ,3R claim 1 ,4S claim 1 ,5S claim 1 ,6R)-3 claim 1 ,4 claim 1 ,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-yl 3-(3 claim 1 ,4-dihydroxyphenyl)acrylate (“Ribetril A”).4. The alkaloid fraction according to claim 3 , wherein said at least one compound according to formula (II) is selected from the group consisting of:(E)-(E)-2-cyano-4-(β-D-glucopyranosyloxy)but-2-en-1-yl 3-(4-hydroxy-3-methoxyphenyl)acrylate (“Ribetril B”);(E)-(E)-2-cyano-4-(β-D-glucopyranosyloxy)but-2-en-1-yl 3-(4-hydroxyphenyl)acrylate (“Ribetril C”);(E)-2-cyano-4-(β-D-glucopyranosyloxy)but-2-en-1-yl 4-hydroxy-3-methoxybenzoate (“Ribetril D”);(E)-2-cyano-4-(β-D-glucopyranosyloxy)but-2-en-1-yl 4-hydroxybenzoate (“Ribetril E”).5. The alkaloid fraction according to claim 3 , wherein said at least one compound according to ...

METHODS OF PRODUCING GLYCOLIPIDS

Provided are methods and yeast cultures for producing glycolipids and glycolipid compositions. 1. A yeast culture comprising: a population of basidiomycetous yeast cells , one or more hydrophilic carbon sources , and/or at least about 1 g/L glycolipid , wherein the culture does not comprise one or more hydrophobic carbon sources.2. The yeast culture of claim 1 , wherein the culture does not comprise one or more hydrophobic carbon sources selected from the group consisting of oils claim 1 , hydrocarbons claim 1 , unsaturated hydrocarbons claim 1 , fatty acids claim 1 , fatty esters including glycerides and mixtures thereof claim 1 , alcohols claim 1 , diols claim 1 , sterols claim 1 , waste streams claim 1 , lignocellulosic hydrolysates claim 1 , and mixtures thereof.3. A yeast culture comprising: a population of basidiomycetous yeast cells claim 1 , one or more hydrophilic carbon sources claim 1 , one or more hydrophobic carbon sources and at least about 1 g/L glycolipid.4. The yeast culture of any one of to claim 1 , wherein the culture comprises less than about 2% (w/v) nitrogen.5. The yeast culture of any one of to claim 1 , wherein the culture comprises nitrogen in the range of about 0.005% (w/v) to about 2% (w/v).6. The yeast culture of any one of to claim 1 , wherein the nitrogen source is selected from the group consisting of ammonia claim 1 , ammonium salt claim 1 , nitrate claim 1 , nitrite claim 1 , nucleotides claim 1 , nucleosides claim 1 , proteins claim 1 , peptides claim 1 , amino acids claim 1 , urea and its derivatives claim 1 , and mixtures thereof.7. The yeast culture of any one of to claim 1 , wherein the culture comprises about 0.05% (w/v) ammonium chloride.8. The yeast culture of any one of to claim 1 , wherein the culture comprises one or more hydrophilic carbon sources at a concentration in the range of about 0.2% (w/v) to about 70% (w/v).9. The yeast culture of any one of to claim 1 , wherein the culture comprises a carbon to nitrogen ratio ...

MONOMER FOR SYNTHESIS OF RNA, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING RNA

The objective of the present invention is to provide a monomer for RNA synthesis which can be efficiently produced and therefore by which the producing cost of RNA can be remarkably decreased, and a method for efficiently producing the monomer in a small number of steps. In addition, the objective of the present invention is also to provide a method by which RNA can be efficiently produced even when a approximately stoichiometry amount of the monomer for RNA synthesis is used. The monomer for RNA synthesis according to the present invention is represented by the following formula (I) or (I′): 2. (canceled)7. The method according to claim 6 , further comprising the step of removing the R—(C═O)— group at the 2′-position and the X—(C═O)— group at the 3′-position by a lipase or an esterase.8. The method according to claim 7 , wherein the step of removing the R—(C═O)— group at the 2′-position and the X—(C═O)— group at the 3′-position is carried out in a solvent containing a Calcohol.10. The monomer for RNA synthesis or a salt thereof according to claim 1 , wherein B is adenine claim 1 , guanine claim 1 , cytosine claim 1 , uracil claim 1 , hypoxanthine and xanthine and is not protected.11. The monomer for RNA synthesis or a salt thereof according to claim 1 , used for liquid phase synthesis of RNA.12. The monomer for RNA synthesis or a salt thereof according to claim 1 , wherein Ris a silyl protective group selected from trimethylsilyl claim 1 , triethylsilyl claim 1 , triisopropylsilyl claim 1 , dimethylisopropylsilyl claim 1 , diethylisopropylsilyl claim 1 , dimethylthexylsilyl claim 1 , t-butyldimethylsilyl claim 1 , t-butyldiphenylsilyl claim 1 , tribenzylsilyl claim 1 , tri-p-xylylsilyl claim 1 , triphenylsilyl claim 1 , diphenylmethylsilyl and t-butylmethoxyphenylsilyl.13. The method according to claim 6 , wherein B is adenine claim 6 , guanine claim 6 , cytosine claim 6 , uracil claim 6 , hypoxanthine and xanthine and is not protected.14. The method according to ...

Recombinant microorganism for producing crocin and method for producing crocin using the same

Compared with the conventional method for producing crocin, which is produced in small amounts through a part of plants or callus, the production method using the recombinant microorganism of the present disclosure enables mass production of crocin.

Glycosyl transferases and their uses

The present invention relates to novel glycosyl transferases from Vitis vinifera that are capable of catalyzing the formation of certain glycosides with high efficiency, to nucleic acid molecules encoding such glycosyl transferases, to vectors, host cells and transgenic plants comprising nucleic acid sequences coding for such glycosyl transferases, and to methods for preparing and uses of such glycosyl transferases.

Method for producing modified resveratrol

Methods for producing glycosylated and methylated resveratrol in a genetically engineered cell, by bioconversion, and in vitro are disclosed herein.

SOPHOROLIPIDS AS PROTEIN INDUCERS AND INHIBITORS IN FERMENTATION MEDIUM

A method for producing sophorolipids having protein inducer and/or repressor activities having the steps of synthesizing the sophorolipid by fermentation of in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids and then utilizing the natural mixture as a protein inducing agent, utilizing the natural mixture as a protein repressing agent, and/or utilizing the natural mixture as a combined protein induction/repressor agent. An application of the sophorolipid compound produced according to the method as a microbial media component. 1. A method for producing sophorolipids having protein inducer and/or repressor activities comprising the steps of:{'i': 'Candida bombicola', 'a) synthesizing the sophorolipid by fermentation of in a fermentation medium to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids; and'}b) utilizing the natural mixture as a protein inducing agent.2. The method according to claim 1 , wherein the fermentation medium comprises glucose claim 1 , yeast extract claim 1 , urea claim 1 , and oleic acid in water.3. The method according to claim 2 , further comprising claim 2 , after a period of fermentation claim 2 , extracting the sophorolipid using ethyl acetate as a solvent.4. The method according to claim 3 , further comprising removing the solvent and washing the obtained product with hexane to remove residual fatty acids claim 3 , resulting in the natural mixture of sophorolipids.5. The method according to claim 4 , further comprising drying the natural mixture of sophorolipids.6. The method according to claim 1 , further comprising adding an effective amount of the natural mixture of sophorolipids as a protein inducing agent to a microbial culture medium.7. The method according to claim 6 , wherein the protein is selected from the group consisting of amylase claim 6 , laccase claim 6 , and manganese peroxidase claim 6 , and combinations thereof.8. A method for producing ...

PROCESS FOR THE PREPARATION OF HALO-SUBSTITUTED TRIFLUOROACETOPHENONES

The invention relates to a process for the preparation of a compound of formula I (I), wherein Ris hydrogen, fluoro or chloro; which process comprises a) reacting a compound of formula II (II), wherein Ris hydrogen, fluoro or chloro; with a nitration agent to the compound of formula (III), wherein Ris hydrogen, fluoro or chloro; and b) reacting the compound of formula III with chlorine gas at temperature from 180° C. to 250° C. to the compound of formula I. 2. A process according to claim 1 , characterised in that the nitration agent is selected from sulfuric acid claim 1 , nitric acid and their salts. The present invention relates to the preparation of halo-substituted 1-aryl-2,2,2-trifluoro-ethanones (compounds Ia, Ib and Ic):and to intermediates useful for this process. Said compounds are important intermediates for the preparation of pesticidally active isoxazoline-substituted benzamides as for example 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone (Ic) disclosed in EP 1932836A1.Typically said compounds of formula Ia, Ib and Ic are synthesized by reaction of corresponding organometallic reagents derived from halo-substituted 5-bromo benzenes of formuae IIa, IIb and IIcwith the derivatives of trifluoroacetic acid (for example ethyl trifluoroacetate). For example, the preparation of 2,2,2-trifluoro-1-(3,4,5-trichlorophenyl)ethanone (I b) is described in WO 2012/120135.The corresponding bromo derivatives of the formulae IIa, IIb and IIc are not easily available and prepared via multistep procedures. For example, 5-bromo-1,2,3-trichloro-benzene (II b) can be prepared as described in Narander, N.; Srinivasu, P.; Kulkarni, S. J.; Raghavan, K. V. Synth. Comm. 2000, 30, 3669 and Sott, R.; Hawner, C.; Johansen, J. E. Tetrahedron 2008, 64, 4135.5-bromo-1,3-dichloro-2-fluoro-benzene (II c) is especially difficult to prepare in particular on a large scale with the only described synthesis being an inefficient multistep approach described in Miller, M. W.; Mylari, ...

Production of Steviol Glycosides in Recombiant Hosts

The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors. 1. A recombinant host capable of synthesizing a steviol glycoside , comprising a gene encoding a transporter polypeptide and/or a gene encoding a transcription factor polypeptide that regulates expression of at least one transporter gene;wherein expression of the gene encoding the transporter polypeptide and/or the gene encoding the transcription factor polypeptide that regulates expression of at least one transporter gene is modified and the recombinant host transports at least a portion of the synthesized steviol glycoside from the host into a culture medium.2. The recombinant host of claim 1 , wherein the gene encoding the transporter polypeptide is an endogenous gene.3. The recombinant host of any one of or claim 1 , wherein the transporter polypeptide comprises an ATP-binding cassette (ABC) transporter claim 1 , a major facilitator superfamily (MFS) transporter claim 1 , an amino acid/auxin permease (AAAP) family transporter claim 1 , an ATPase transporter claim 1 , a sulfate permease (SuIP) family transporter claim 1 , a lysosomal cystine transporter (LCT) family transporter claim 1 , a Ca2+:cation antiporter (CaCA) family transporter claim 1 , an amino acid-polyamine-organocation (APC) superfamily transporter claim 1 , a multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) transporter claim 1 , a ZRT/IRT-like protein (ZIP) metal transporter family transporter claim 1 , a mitochondrial protein translocase (MPT) family transporter claim 1 , a voltage-gated ion channel (VIC) family transporter claim 1 , a monovalent cation:proton antiporter-2 (CPA2) family transporter claim 1 , a ThrE family of putative transmembrane amino acid efflux transporter claim 1 , an oligopeptide transporter (OPT) family transporter claim 1 , a K transporter (Trk) family transporter claim 1 , a bile acid:Na symporter (BASS) family transporter claim 1 , a ...

GLYCOLIPOPEPTIDE BIOSURFACTANTS

Surfactants based on a newly discovered class of compounds include a hydrophobic lipid oligomer covalently linked to a peptide or peptide-like chain and a carbohydrate moiety, and a serine-leucinol dipeptide linked to the lipid oligomer. Such surfactants can be used to create an oil-in-water or water-in-oil emulsion by mixing together a polar component; a non-polar component; and the surfactant. Biosurfactants of the newly discovered class can be made by isolating and culturing a microorganism which produces the biosurfactant, and then isolating the biosurfactant from the culture. A microorganism can be engineered to produce biosurfactant of this newly discovered class by expressing a set of heterologous genes involved in the biosynthesis of the biosurfactant in the microorganism. 1. A method of preparing biosurfactants containing rhamnose moieties , comprising adding at least one rhamnose moiety to a biosurfactant with recombinately expressed RlpE.2. The method of claim 1 , wherein the biosurfactant comprises a hydrophobic lipid component comprising a carboxyl end and a hydroxyl end claim 1 , wherein the lipid component is covalently linked to (i) a peptide or peptide-like chain at the carboxyl end of the lipid component and (ii) a carbohydrate moiety comprising at least one rhamnose moiety at the hydroxyl end of the lipid component via a glycosidic linkage.3. The method of claim 2 , wherein the peptide chain comprises in the range of between 2 and 10 amino acids.4. The method of claim 2 , wherein the lipid component comprises in the range of between 1 and 6 alkanoic acid moieties5. The method of claim 2 , wherein the lipid component comprises an acyl chain claim 2 , and wherein the length of each said acyl chain is in the range of between Cto C.6. The method of claim 2 , wherein the carbohydrate moiety may comprise at least one acetyl group.7. The method of claim 2 , wherein the peptide or peptide-like chain comprises a serine-leucinol dipeptide.8. The method of ...

DISTRIBUTED SYSTEMS FOR THE EFFICIENT PRODUCTION AND USE OF MICROBE-BASED COMPOSITIONS

The invention relates to systems and methods for effective production and use of microorganisms and/or the fermentation broth in which they are produced. Advantageously, the system is cost-effective, scalable, quick, versatile, efficacious, and helpful in reducing resistance to chemical compounds and residue that concerns consumers. 1. A system for providing a microbe-based product , wherein said system comprises:(i) a microbe growth facility comprising a plurality of modular growth vessels in which the same, or different, microbes can be grown, under the same, or different, growth conditions to produce a microbe-based composition from each growth vessel, wherein the growth medium, oxygenation, pH, agitation, and/or temperature can be independently controlled for each of said growth vessels; and wherein the microbe-based composition is harvested thereby creating a microbe-based product that can then be provided to a consumer; and(ii) a transportation component for transporting said microbe-based product produced in the microbe growth facility, wherein said transportation component comprises containers and/or conduits to transport the microbe-based product from the microbe growth facility to a distribution center or to a location where the microbe-based product will be used.2. The system claim 1 , according to claim 1 , wherein said microbe growth facility has at least 10 modular growth vessels.3. (canceled)4. The system claim 2 , according to claim 2 , wherein each of said at least 10 modular growth vessels has its own control elements for temperature claim 2 , dissolved oxygen and pH.5. (canceled)6. The system claim 1 , according to claim 1 , wherein the containers in which the microbe-based product are transported are from 2 gallons to 1 claim 1 ,000 gallons claim 1 , or the microbe-based product is transported by conduit to the site of use.722-. (canceled)23. A method for providing a microbe-based product claim 1 , wherein said method comprises growing microbes ...

Methods For Selecting Microbes From A Diverse Genetically Modified Library to Detect and Optimize the Production of Metabolites

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite. 1. A method of selecting a subset of microbes for the production of a metabolite comprisingplacing a population of microbes in an environment of a toxin,wherein the population of microbes has been genetically modified to include exogenous DNA encoding for an antidote to the toxin,wherein the population of microbes has been genetically modified to include exogenous DNA encoding a sensor biomolecule which when expressed regulates expression of the antidote by the microbes through a cognate nucleic acid sequence located 5′ to the antidote gene,wherein the population of microbes has been genetically modified to include exogenous DNA encoding genes to produce a metabolite binding partner of the sensor, which when produced binds to the sensor to induce expression of the antidote in a manner dependent on the concentration of the produced metabolite, andselecting a subset of microbes that produce sufficient metabolite to prevent microbe death.2. The method of further comprisinggenetically modifying the subset of microbes to alter genes that affect production of the metabolite directly or indirectly,subjecting the subset of microbes to a subsequent environment of the toxin having a concentration greater than the previous environment, andselecting a subsequent subset of microbes the produce sufficient metabolite to prevent microbe death.3. The method of further comprisingrepeating in sequence: (1) genetically modifying the subsequent subset of microbes by altering genes that affect the production of the metabolite, (2) subjecting the genetically altered microbes to a subsequent environment of a toxin having a concentration greater than a previous environment, and (3) selecting a further subsequent subset of microbes that produce sufficient metabolite to prevent microbe death, said repeating step resulting in optimized ...

SULFOLIPIDS AS NEW GLUTAMINYL CYCLASE INHIBITORS

The invention relates to the use of a compound of formula (I), or a composition containing the compound, as glutaminyl cyclase (QC) inhibitor and to methods of preparation. 2. The use of the compound of formula (I) or a salt thereof according to claim 1 , wherein{'sup': '1', 'sub': 13', '20', '13', '21, 'Ris a hydrogen atom, —C(═O)C-Calkyl or —C(=O)C-Calkenyl; and'}{'sup': '2', 'sub': 13', '21', '13', '21, 'Ris a hydrogen atom, —C(=O)C-Calkyl or —C(=O)C-Calkenyl.'}3. The use of the compound of formula (I) or a salt thereof according to claim 1 , wherein{'sup': '1', 'Ris a hydrogen atom, a palmitoyl, palmitoleoyl, oleoyl, linoleoyl, linolenoyl, eicosatetraenoyl or an eicosapentaenoyl group; and'}{'sup': '2', 'Ris a hydrogen atom, a palmitoyl, palmitoleoyl, oleoyl, linoleoyl, linolenoyl, eicosatetraenoyl or an eicosapentaenoyl group.'}4. The use of the compound of formula (I) or a salt thereof according to claim 1 , wherein the compound is selected from the group: 1 claim 1 ,2-di-O-palmitoyl-3-O-(6′-deoxy-6′-sulfo-D-glycopyranosyl claim 1 , 1-O-palmitoyl-2-O-linolenyl-3-O-(6′-deoxy-6′-sulfo-D-glycopyranosyl claim 1 , 1-O-linolyl-2-O-palmitoyl-3-O-(6′-deoxy-6′-sulfo-D-glycopyranosyl claim 1 , 1-O-palmitoyl-3-O-(6′-sulfo-α-quinovopyranosyl)-glycerol and 1-O-(6-deoxy-6-sulfoglucopyranosyl)-glycerol.6. The use of the composition according to claim 5 , wherein the composition is an extract from a microalga.7. The use of the composition according to claim 5 , wherein the composition also contains a solvent.8. The use of the composition according to claim 7 , wherein the solvent is selected from: methanol claim 7 , ethanol claim 7 , isopropanol claim 7 , water claim 7 , chloroform claim 7 , ethyl acetate claim 7 , dichloromethane claim 7 , acetone claim 7 , diethyl ether claim 7 , hexane and mixtures thereof.9. The use of the composition according to claim 5 , wherein the composition comprises two claim 5 , three or more than three compounds according to formula (I) or salts ...